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ABSTRACT  
Lesser, S. Influence of Dietary Fat on the Oral Bioavailability of the Flavonol Quercetin. 
Doctoral dissertation, University of Kiel, 2006 
 
A multitude of potentially beneficial health effects are presently discussed to be exerted by flavonoids, 
a group of secondary plant metabolites. Knowledge about the bioavailability of these agents is a 
prerequisite for the estimation of their potential in vivo effects. The flavonol quercetin is one of the 
most predominant flavonoids with regard to quantity in the Western-style human diet and it is also one 
of the most studied. In plants and plant-derived food, quercetin dominates in its glycosilated form. 
Both the chemical composition of the sugar moieties and their position(s) influence the intestinal 
absorption of quercetin. In addition, the composition of the diet may exert an influence on the 
bioavailability of quercetin. The present study investigated the influence of the amount of dietary fat 
as well as the influence of the chemical composition of dietary fat (long-chain triacylglycerols, LCT, 
vs. medium-chain triacylglycerols, MCT) on the oral bioavailability of co-ingested quercetin in pigs. 
The first study investigated the influence of different amounts of dietary fat in a test meal (enriched 
with lard; 3, 17, or 32% crude fat content) on the oral bioavailability of quercetin either applied as 
aglycone or as quercetin-3-O-glucoside (30 µmol/kg body weight). It was shown that an increase in 
the dietary fat content from 3 to 17% (wt/wt) significantly enhanced the bioavailability of quercetin 
with both sources of quercetin (aglycone and monoglucoside). No further enhancing effect on 
quercetin’s bioavailability was observed with a diet containing 32% fat. 
The second study was aimed to investigate the influence of the fatty acid pattern of dietary fat (LCT 
vs. MCT, 16% crude fat content) on the bioavailability of quercetin applied as aglycone. Intake of 
quercetin with the LCT as well as the MCT diet, compared with the low-fat diet, enhanced the 
bioavailability of quercetin by 12 and 38%, respectively, which was significant for the MCT diet only. 
The pharmacokinetic parameters of quercetin in plasma, however, were significantly influenced by the 
type of dietary fat. Maximal plasma levels of quercetin in the systemic circulation were reached 
significantly later with the MCT diet compared with the LCT or the low-fat diet. As no differential 
effect of the experimental diets on gastric emptying was observed in an additional experiment 
performed in rats, a delay in gastric emptying triggered by MCT diet might be largely excluded as a 
potential cause of the findings. 
In summary, it is demonstrated that both the fat content and the fatty acid pattern of dietary fat 
influence the oral bioavailability of the plant polyphenol quercetin. With respect to the systemic 
availability of dietary flavonoids, diet composition has to be considered as an important factor. 
 

ZUSAMMENFASSUNG  
Lesser, S. Einfluss von Nahrungsfett auf die orale Bioverfügbarkeit des Flavonols Quercetin. 
Dissertation, Universität Kiel, 2006 
 
Für Flavonoide, eine Gruppe sekundärer Pflanzenmetabolite, werden eine Reihe potenziell 
gesundheitsfördernder Wirkungen diskutiert. Voraussetzung für die Einschätzung ihrer möglichen 
Wirkungen im menschlichen und tierischen Organismus ist eine ausreichend hohe Bioverfügbarkeit. 
Quercetin ist eines der quantitativ und qualitativ bedeutendsten Flavonole aus der Gruppe der 
Flavonoide. In Pflanzen und in pflanzlichen Lebensmitteln liegt Quercetin vorwiegend glykosidisch 
gebunden vor. Sowohl die chemische Zusammensetzung als auch die Position des/der verknüpften 
Zuckerreste(s) beeinflussen die intestinale Aufnahme von Quercetin. Zusätzlich scheint auch die 
Zusammensetzung der Mahlzeit einen Einfluss auf die systemische Verfügbarkeit von Quercetin 
auszuüben. In der vorliegenden Arbeit wurde sowohl der Einfluss des Fettgehaltes als auch der 
mögliche Einfluss der Fettsäurenkettenlänge (langkettige Triacylglycerine, LCT, vs. mittelkettige 
Triacylglycerine, MCT) in der Nahrung auf die orale Bioverfügbarkeit von zeitgleich 
eingenommenem Quercetin an Schweinen untersucht. 
In der ersten Studie wurde der Einfluss unterschiedlicher Fettgehalte einer Testmahlzeit (angereichert 
mit Schmalz; 3, 17 bzw. 32% Rohfettgehalt) auf die orale Bioverfügbarkeit von Quercetin (Aglykon 
oder Quercetin-3-O-Glukosid; 30 µmol kg-1 Körpergewicht) untersucht. Dabei zeigte sich, dass eine 
Erhöhung des Nahrungsfettgehaltes von 3 auf 17% (wt/wt) die systemische Verfügbarkeit von 
Quercetin unabhängig von der applizierten chemischen Form (Aglykon oder Monoglukosid) 
signifikant steigert. Eine Erhöhung des Fettgehaltes der Testmahlzeit auf 32% führte zu keiner 
weiteren Steigerung der Bioverfügbarkeit von Quercetin. 
Die zweite Studie untersuchte den Einfluss der Fettsäurenkettenlänge (LCT vs. MCT; 16% 
Nahrungsfettgehalt) auf die systemische Verfügbarkeit von Quercetin. Die Einnahme von Quercetin 
mit einer LCT- bzw. MCT-haltigen Testmahlzeit erhöhte die systemische Verfügbarkeit von Quercetin 
gegenüber der Einnahme ohne zusätzliches Fett (Standard Diät, 2% Fettgehalt) um 12 bzw. 38%, 
wobei der Effekt mit der LCT Diät nicht signifikant ausfiel. Die pharmakokinetischen Parameter von 
Quercetin im Plasma wurden signifikant durch die Art des Nahrungsfettes beeinflusst. Maximale 
Quercetin-Plasmaspiegel wurden signifikant später bei Einnahme mit MCT Diät im Vergleich zur 
LCT bzw. Standard Diät erreicht. Eine verzögerte Magenentleerung als Erklärung für diese Befunde 
wurde weitgehend ausgeschlossen, da in einer ergänzenden Studie an Ratten kein Unterschied in der 
Magenleerung nach Einnahme der verschiedenen Diäten beobachtet wurde. 
Zusammenfassend konnte gezeigt werden, dass sowohl der Gehalt als auch die Fettsäurenkettenlänge 
von Nahrungsfett die orale Bioverfügbarkeit des pflanzlichen Polyphenols Quercetin beeinflussen. 
Somit hat die Zusammensetzung einer Mahlzeit einen signifikanten Einfluss auf die systemische 
Verfügbarkeit von Flavonoiden aus der Nahrung. 
 

 TABLE OF CONTENTS 
 
 
ABBREVIATIONS 
LIST OF TABLES 
LIST OF FIGURES 
 
 
GENERAL INTRODUCTION 
................................................................................................................................................   1 
CHAPTER ONE 
ORAL BIOAVAILABILITY OF THE FLAVONOL QUERCETIN – A LITERATURE REVIEW 
................................................................................................................................................   3 
CHAPTER TWO 
BIOAVAILABILITY OF QUERCETIN IN PIGS IS INFLUENCED BY THE DIETARY FAT CONTENT 
................................................................................................................................................  41 
CHAPTER THREE 
THE FATTY ACID PATTERN OF DIETARY FATS INFLUENCES THE ORAL BIOAVAILABILITY OF  
THE FLAVONOL QUERCETIN IN PIGS 
................................................................................................................................................  55 
CHAPTER FOUR 
GENERAL DISCUSSION 
................................................................................................................................................  71 
APPENDIX 
................................................................................................................................................  82 
 
  
 ABBREVIATIONS 
 
 
ABC ATP-binding cassette  
ATP adenosine triphosphate 
AUC area under the curve 
BBM brush border membrane 
BCRP2 breast cancer resistance protein 2 
BSA bovine serum albumin 
BW body weight 
c480, c720 plasma concentration at 480 or 
720 min after ingestion of test 
meal, respectively 
CBG cytosolic β-glycosidase 
CCK cholecystokinin 
cmax maximal plasma concentration 
CO2 carbon dioxide 
COMT catechol-O-methyl-transferase 
CVD cardiovascular diseases 
DMSO dimethyl sulfoxide 
g acceleration of gravity, 9.81 m s-2 
GIT gastrointestinal tract 
HSA human serum albumin 
i.v. intravenous 
LCT long-chain triacylglycerols 
LDL low-density lipoproteins 
LPH lactase-phloridzin hydrolase 
LSM least-squares means 
MCT medium-chain triacylglycerols 
MRP2 multidrug resistance associated 
protein 2 
NEFA non-esterified fatty acids 
P octanol/water partition coefficient 
P probability 
p-gp p-glycoprotein 
Q3G quercetin-3-O-glucoside 
Q3,4’diG quercetin-3-O, 4’-O-diglucoside 
Q4’G quercetin-4’-O-glucoside 
SEM standard error of the mean 
SGLT1 sodium-dependent glucose  
co-transporter 1 
tmax time at maximal plasma 
concentration 
v volume 
wt weight 
 
 LIST OF TABLES 
 
 
Table I.1 Flavonoids content in selected plant food …………………………….…..…. 8 
Table II.1 Compostition of the diets ……………………………………………….…… 44 
Table II.2 Relative bioavailability and pharmacokinetic parameters of quercetin  
 in pigs after intake of quercetin aglycone or quercetin-3-O-glucoside  
 in test meals differing in their fat content …………………………………… 46 
Table III.1 Compostition of diets ……………………………………………………….. 58 
Table III.2 Pharmacokinetic parameters and relative bioavailability of quercetin  
 in pigs after intake of quercetin in test meals differing in their fat content 
 and/or fatty acid pattern …………………………………………………….. 61 
Table IV.1 Pharmacokinetic parameters and urinary fractional excretion of intact  
 quercetin in humans after consumption of ~100 mg quercetin equivalents  
 as aglycone, glycosides, or with food .…………………………………….… 75 
Table A Mean fatty acid composition of lard (Belitz & Grosch, 1992) ……………… 84 
 
 
 LIST OF FIGURES 
 
 
Figure I.1 Basic chemical structures of the main flavonoid subclasses ……………….... 6 
Figure I.2 Chemical structure of selected flavonols ………………………………….…. 7 
Figure I.3 Model of a plasma concentration-time curve after administration of  
 a single oral dose ……………………………………………………………. 12 
Figure I.4 Model for prediction of the absorption of polyphenols in humans  
 based on evidence from in vivo and in vitro studies (Scalbert &  
 Williamson, 2000) ……………………………………………….......……… 16 
Figure II.1 Plasma concentration-time curves of quercetin after oral administration  
 of quercetin aglycone or of quercetin-3-O-glucoside (inset) to pigs (30  
 µmol/kg BW each) in test meals that differed in their fat content ……….…. 47 
Figure III.1 Plasma concentration-time curves of the main metabolite quercetin after  
 oral administration of quercetin (30 µmol/kg BW) to pigs in test meals  
 that differed in their fat content and/or fatty acid pattern …………………… 62 
Figure III.2 Gastric content of rats 1 h after administration of 5 g test meals that  
 differed in their fat content and/or fatty acid pattern (dry matter expressed 
 as percentage of intake) …………………………………………………...… 63 
 
 

  1 
GENERAL INTRODUCTION 
Flavonoids are secondary plant metabolites possessing a polyphenol structure. In the 1930ies, 
flavonoids were thought to have vitamin properties, whereas they were considered as potential 
mutagens and carcinogens in the 1970ies. The attention focused on their anti-mutagenic and 
anti-carcinogenic activities in the 1980ies. In recent years, the antioxidant properties of 
flavonoids and their potential role in both, inhibition of low-density lipoprotein (LDL) 
oxidation and platelet aggregation, were reported (Hertog, 1996). Protective properties of 
flavonoids in conjunction with so-called ‘free radical diseases’, such as cardiovascular 
diseases (CVD), cancer, or cataract, are actually discussed and, in case of CVD, are supported 
by epidemiological studies. These findings have resulted in increased interest in the health-
promoting aspects of flavonoids.  
In order to evaluate their bioactivity in vivo, it is necessary to understand the factors 
influencing the absorption of flavonoids by the gastrointestinal tract and the nature of the 
conjugates and metabolites present in the circulation. This work is aimed to contribute to our 
knowledge on nutritional factors influencing oral bioavailability of flavonols, a bioactive and 
abundant subgroup of flavonoids, and to gain further insight into the mechanisms of flavonol 
absorption. 
The first chapter of this thesis gives an overview on the present knowledge on flavonol 
bioavailability, with special emphasize on the flavonol quercetin. Quercetin is an abundant 
flavonoid in vegetal food, and due to its potent antioxidative properties it is also one of the 
most investigated polyphenols. In the second chapter, a study on the bioavailability of 
quercetin aglycone and quercetin-3-monoglucoside (isoquercitrin, Q3G) fed to pigs in test 
meals with different fat content is described. In a subsequent study, presented in chapter III, 
the influence of the fatty acid chain length of dietary triacylglycerols on flavonol 
bioavailability is examined. Chapter IV presents a general discussion of the results of both 
studies. In the appendix, preparation of the plasma samples and HPLC analysis are described 
in detail, as the methods are only briefly summarized in the two manuscripts. In addition, 
information on the fatty acid composition of lard used as experimental fat in the own studies 
is provided.  
REFERENCE 
Hertog MGL (1996) Epidemiological evidence on potential health properties of flavonoids. Proc Nutr 
Soc 55, 385-397. 
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Oral Bioavailability of the Flavonol Quercetin – A Literature Review. 
 
I.1. Introduction 
I.2. Structure and sources of flavonoids 
I.3. Bioavailability of flavonols 
I.3.1. General aspects of bioavailability 
I.3.2. Bioavailability of quercetin 
 I.3.2.1. Absolute systemic availability  
 I.3.2.2. Mechanisms of intestinal absorption 
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I.3.3.1. Physico-chemical aspects  
I.3.3.2. Lactase-phloridzin hydrolase (LPH) 
I.3.3.3. Intestinal efflux transporters 
I.3.3.4. Intestinal microflora 
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I.1. Introduction 
Flavonoids are secondary plant metabolites synthesized in virtually all higher plants. Together 
with lignans, stilbenes and phenolic acids they make up the highly diverse group of 
polyphenols (Scalbert & Williamson, 2000). Due to their wide distribution in the plant 
kingdom, they are present in many plant-derived foodstuffs. Primarily present in onions, 
apples, kale, broccoli and black tea they are part of the daily nutrition. Early interest in 
polyphenols was related to their “antinutritional” effects, i.e. decreasing absorption and 
digestibility of food through their ability to bind proteins and minerals. The astringency of 
many fruits and beverages is attributable to the precipitation of salivary proteins by plant 
polyphenols. Current interest is focussing on the beneficial health effects of dietary 
polyphenols. For hundreds of years, flavonoid rich plants are used in traditional medicine of 
many ethnics. Epidemiological studies have suggested associations between the consumption 
of polyphenol-rich food and beverages and the prevention of diseases (Rice-Evans et al., 
2000). Flavonoids are the most abundant polyphenols in our diets (Scalbert & Williamson, 
2000). They are powerful antioxidants in vitro, but their overall functions in vivo have yet to 
be clarified, whether antioxidant, anti-inflammatory, enzyme inhibitor or inducer, or some 
other role (Rice-Evans et al., 2000).  
With the ‘Western Diet’, daily consumption of the main flavonoids quercetin, kaempferol, 
myricetin (flavonols), apigenin and luteolin (flavones) sums up to approximately 20-30 mg d-1 
(Hertog et al., 1993b). The flavonol quercetin is one of the most abundant flavonoids in plants 
and plant-derived food (Hertog et al., 1992). In some countries and also via the internet, 
quercetin can already be purchased as an over-the-counter food supplement (Weldin et al., 
2003). Anyhow, it seems too early to suggest supplemental intake exceeding the amount 
consumed with an optimised plant-food based mixed diet. Bioavailability is a prerequisite for 
potential health effects, and yet there are still unsolved questions concerning flavonoids. Due 
to quite intense research on the gastrointestinal uptake and metabolism of flavonoids over the 
past decade, using humans, animal models and cell culture studies, a general working 
hypothesis has been established (chapter I.3.2.1.) (Scalbert & Williamson, 2000). Most 
recently, emphasis in research is drawn on factors affecting flavonoids bioavailability, such as 
alternative routes of uptake other than via portal vein blood (Murota & Terao, 2005), the food 
matrix (Wiczkowski et al., 2003; Graefe et al., 2001; de Vries et al., 2001), or the influence of 
co-administered nutrients (Goldberg et al., 2003; Azuma et al., 2003). 
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I.2. Structure and sources of flavonoids 
Flavonoids are widespread in the plant kingdom, with exception of algae and fungi (Bravo, 
1998). In plants, this secondary metabolites exert controlling effects on the amount of 
phytohormons of growth and differentiation, play a vital role in catalysing transport of 
electrons in photosynthesis and have antioxidative, antifungal and antibacterial effects, thus 
contributing to the defence system of the plants (Harborne & Williams, 2000). This defence 
function might be supported by the many studies that indicate mutagenic responses of cell 
cultures to polyphenols like quercetin (Brusick, 1993). On the other hand, there is very little 
evidence to date to suggest that dietary polyphenols promote adverse metabolic reactions in 
vivo when consumed in nutritionally relevant and also much higher quantities. Polyphenols 
are partially responsible for the sensory and nutritional qualities of vegetal food, as 
astringency and bitterness of foodstuffs and beverages depends on their content of 
polyphenolic compounds. Several thousand of different flavonoids have been identified in 
plants, with large diversity in their structural features. Classification of flavonoids in different 
subclasses is based on variations in their carbon skeleton (Bravo, 1998). In Figure I.1, the six 
main subclasses are shown (Rice-Evans et al., 1996). 
The large structural diversity of flavonoids with presently more than 6000 different known 
forms (Harborne & Williams, 2000) is mainly due to different oxidation states of the 
heterocyclic ring, the pattern of hydroxylation, glycosilation, acylation with phenolic acids, 
and by the existence of stereoisomers, among other factors. Most flavonoids are usually found 
in plants bound to sugars as O-glycosides. Flavones may also occure as C-glycosides. The 
only exception to this rule are the flavanols, such as catechins and procyanidins, which are 
almost always present in the diet in the non-glycosilated form (Rice-Evans et al., 1996). 
Predominantly, the bonds are beta-glycosidic and sugar moieties might be mono-, di- or 
oligosaccharides. The associated sugar moiety is very often glucose or rhamnose, but other 
sugars may also be involved (e.g. galactose, arabinose, xylose, glucuronic acid) (Manach et 
al., 2004). The sugar molecules can bind to various positions in the parent flavonoid, although 
there is a preference for the 3-position (Hollman & Arts, 2000). About 150 naturally 
occurring glycosides of quercetin alone have been described (Williams & Harborne, 1994). 
Structures of selected flavonols are shown in Figure I.2. Free flavonoids, i.e. flavonoids 
without attached sugars, are named aglyca. Aglyca of flavonoids may be present in plant-
derived food mainly as a result of storage and processing (Hollman & Arts, 2000). 
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Flavones 
General structure 
 
 
 
Flavonols 
 
Flavanols 
(Catechins) 
 
 
 
Flavanones Anthocyanidins 
 
 
 
 
Flavanonols Isoflavones 
 
 
 
Figure I.1: Basic chemical structures of the main flavonoid subclasses 
 
Synthesis of flavonoids by plants depends on light. Therefore, highest concentrations of 
flavonols and flavones occure in the epidermis of the sun-exposed parts of leafs and in the 
peel of fruits while only trace amounts are found below the soil surface (Hertog, 1996). An 
exception are onions which contain a large amount of quercetin glucosides (Price & Rhodes, 
1997). Marked differences in concentrations of flavonoids exist between pieces of fruit in the 
same tree and even between different sides of a single piece of fruit, depending on exposure to 
sunlight (Price et al., 1995). Traditionally used herbs and medicinal plants often have a high 
flavonoid content by nature, e.g. calendula flowers, ginkgo biloba leafs, elder flower, 
goldenrod, red clover or fennel seeds (Pietta et al., 2003).  
Flavonols, a sub-group of flavonoids, are present in human diets predominantly as quercetin 
and kaempferol. In vegetables, quercetin glycosides predominate, but glycosides of 
kaempferol, luteolin, and apigenin are also present (Herrmann, 1988). Quercetin levels in 
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vegetables were found to be generally below 10 mg kg-1, except for onions, beans, broccoli 
and kale. Seasonal variations were found to be large in leafy vegetables such as lettuce and 
endive, which agrees with the light-dependency of flavonoid synthesis (Hertog et al., 1992). 
Fruits contain almost exclusively quercetin glycosides (Herrmann, 1988). In most fruits the 
quercetin content averages 15 mg kg-1, except for apples, apricot and black currants (37 mg 
kg-1) (Hollman & Arts, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 R1 R2 R3 R4 
Quercetin OH OH H OH 
Kaempferol H OH H OH 
Myricetin OH OH OH OH 
Isorhamnetin OCH3 OH H OH 
Tamarixetin OH OCH3 H OH 
Rhamnetin OH OH H OCH3 
Isoquercitrin 
(= Quercetin-3-O-Glucoside, Q3G) 
Figure I.2: Chemical structure of selected flavonols 
 
Apart from sun exposure, numerous additional factors may influence the flavonoid content of 
plants: variety, environmental factors like pathogen exposure, ripeness at the time of harvest, 
processing and storage (Asami et al., 2003). As flavonoids are not evenly distributed in plant 
tissue, food fractionation during processing may result in a loss or enrichment. Simple peeling 
of fruits and vegetables can eliminate significant portions of polyphenols. In apples, for 
example, quercetin is located in the peel of certain cultivars with up to 1 g kg-1 fresh weight, 
while the peeled fruit contains no more quercetin glycosides at all (Burda et al., 1990). 
Cooking may also have major effects. Onions and tomatoes, for example, lose ~75-80% of 
their initial quercetin content after boiling for 15 min, 65% after cooking in a microwave 
oven, and ~30% after frying (Crozier et al., 1997). Mean levels of some flavonoids in selected 
plant food (raw material) are shown in Table I.1.  
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Table I.1: Flavonoids content in selected plant food1 
Food source Flavonoid Content 
Apples Quercetin 
(+)Catechin 
(-)Epicatechin 
20-362 
0-173 
2-1013 
Apricot Quercetin 
(+)Catechin 
(-)Epicatechin 
25-262 
26-573 
67-1713 
Bean, French Quercetin 
Kaempferol 
392 
<122 
Black currant Quercetin 
Kaempferol 
372 
12 
Broccoli Quercetin 
Kaempferol 
434 
944 
Endive Quercetin 
Kaempferol 
<12 
44-2465, 462 
Grape, black Quercetin 
Myricetin 
158 
52 
Grape, white Quercetin 
Myricetin 
128 
52 
Kale Quercetin 
Kaempferol 
1108 
2118 
Onion Quercetin 86-16947, 3478 
Pear Quercetin 68 
Plum Quercetin 98-152 
Salad varieties/ lettuce Quercetin 0-1575 
Strawberry Quercetin 
Kaempferol 
98 
128 
Tea infusion,  
black and green 
Quercetin 
Kaempferol 
Myricetin 
(-)Epicatechin 
10-259 
7-179 
2-59 
31-792 
Tomato Quercetin 
Kaempferol 
1-226, 88 
0-16 
Wine, red Quercetin 
Myricetin 
(+)Catechin 
(-)Epicatechin 
4-169 
7-99 
0-2082 
15-882 
 
1(Hollman & Arts, 2000), modified. Contents in mg kg-1 fresh weight or mg L-1 (only edible portions are 
considered), 2(Hollman & Arts, 2000), 3(Risch & Herrmann, 1988), 4(Price et al., 1997), 5(DuPont et al., 
2000), 6(Stewart et al., 2000), 7(Price & Rhodes, 1997), 8(Hertog et al., 1992), 9(Hertog et al., 1993a). 
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Because flavonoids are ubiquitously present in the plant kingdom, daily consumption of 
flavonoids with plant food can be assumed (Kühnau, 1976). The amount of daily intake 
depends on the specific diet of an individual and also varies with the flavonoid content in 
vegetal food and, therefore, is difficult to estimate. In addition, a lack of standardized 
analytical methods and the structural diversity of flavonoids have complicated estimation of 
their food content. In 1976, Kühnau et al. (1976) estimated intake of flavonoids in the USA to 
be as high as 1 g per day, which nowadays is regarded as overestimated (see below). Based on 
the determination of the content of five major flavonoids in food (Hertog et al., 1992; Hertog 
et al., 1993a), the association between intake of these flavonoids and disease occurrence in 
human subjects became calculable. Since March 2003, a database in which the flavonoid 
contents of 225 selected food and beverages are compiled from 97 bibliographic sources has 
been available on the US Departement of Agriculture webside 
(www.nal.usda.gov/fnic/foodcomp). Generally, databases are currently established (Watanabe 
et al., 2004). This should allow more accurate estimations of dietary intake from dietary 
consumption monitoring. With regard to the fact that flavonoids are naturally present as 
glycosides in plants and the varying bioavailability of different flavonoid glycosides, 
however, compiling food composition tables with individual glycosides rather than the aglyca 
should be considered (Arts et al., 2004). 
In Western Europe, main intake of flavonoids with diet takes place in form of apples, onions, 
broccoli, berries, black and green tea, chocolate and red wine. Consumption of flavonols has 
been estimated to be in the range of 20-25 mg d-1 in Denmark, The Netherlands, and the USA. 
Quercetin intake was shown to vary from 3-34 mg d-1 (reported for 10th and 90th percentile, 
respectively) in between Dutch individuals, with a medium of 16 mg d-1 (Hertog et al., 
1993c). Mean consumption of flavonols and flavones in The Netherlands was 23 mg d-1 (n = 
509), whereby quercetin accounted for the highest portion (~65%), as was similarily observed 
by Sampson et al. (2002) for US American health professionals (~75%)(n = 116 772). In 
another huge cohort study on 34 789 male American health professionals, the average total 
intake of flavonols and flavones was estimated to be 20.1 mg d-1; the 3 primary flavonols 
ingested were quercetin (15.4 mg d-1), kaempferol (3.6 mg d-1), and myricetin (0.9 mg d-1), 
composing more than 90% of the flavonoids ingested by the study cohort (Rimm et al., 1996). 
In a Finnish cohort, median flavonoid intake was only 3.4 mg d-1, but ranged from 0-41.4 mg 
d-1. On average, about 95% of the total flavonoid intake was quercetin. The main sources of 
flavonoids were apples and onions (Knekt et al., 1996). Using data from the Seven Countries 
study, Hertog et al. (1995) stated that in West Finland the only dietary flavonoid might be 
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quercetin. Taken together, quercetin intake reported in this study varied from 2.6 (West 
Finland) to 34.6 (Japan) mg d-1 with an average of ~18 mg d-1 throughout several regions of 
Europe, the USA and Japan. Arai et al. (2000) calculated an amount of 9.3 mg d-1 quercetin 
consumed by 115 Japanese women, with 16.7 mg d-1 as the sum of flavonols and flavones. 
Mean intake of flavonols in the German population was calculated using data from the 
National German Food Consumption Survey by Böhm et al. (1998). According to this 
analysis, daily per capita intake was 11.5 mg flavonols, mainly derived from fruits and 
vegetables, but also from black tea and red wine. In the Bavarian population, mean daily 
flavonol consumption was ~12 mg, with quercetin accounting for the largest portion of 10.3 
mg (Linseisen et al., 1997). Total flavonoid intake in Bavaria was 54 mg d-1. 
Thus, quercetin constitutes at least a significant percentage of total daily dietary flavonoid 
intake. Additionally, it is one of the most intensively studied polyphenolic compound in 
human diet due to its particular biological activities (Scalbert & Williamson, 2000). In 
comparison to the amount of dietary intake of some well established vitamins, e.g. vitamin C 
(~115 mg d-1), vitamin E (~14 mg α-tocopherol equivalents d-1), and pro-vitamin A (β-
carotene, ~2.8 mg d-1) (Karg, 2004), the level of daily flavonoid intake is considerably high. 
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I.3. Bioavailability of flavonols 
Biological effects of any substance depend on its bioavailability. After giving a brief 
introduction into bioavailability and pharmacokinetic parameters in general, this chapter 
focuses primarily on those aspects concerning the bioavailability of flavonols, with special 
emphasis on quercetin, with regard to the subject of this thesis.  
 
I.3.1. GENERAL ASPECTS OF BIOAVAILABILITY 
Bioavailability of a substance is determined by its absorption, disposition, metabolism, and 
excretion (ADME). Drug metabolism occurs already during first pass (in the gut mucosa and 
liver) and thereafter by second pass (organ/tissue specific) metabolism. In a nutritional sense, 
apart from the amount of a dietary substance and its effective metabolites reaching the 
systemic circulation (and thereby other body tissues), the critical concentration required for 
biological activity as well as its biological effect(s) are also comprised in the definition of 
bioavailability. In vitro or cell culture experiments can only address partial aspects of 
bioavailability, such as cellular mechanisms of absorption, biological effects on certain cell 
types, etc. Thus, estimation of true bioavailability can only be done from experiments using 
intact individuals. 
Bioavailability of a compound is usually determined by its concentration-time profile in the 
systemic circulation. One has to keep in mind, however, that blood sampling does not yield 
information on organ- or tissue-specific distribution, accumulation, and metabolism.  
Pharmacokinetic parameters of a substance are derived from the plasma concentration-time 
curve. The area under the plasma concentration-time curve (AUC) is generally used as a 
measure of bioavailability (Figure I.3). Other parameters of interest with regard to 
bioavailability of a substance are the maximal plasma concentration (cmax), time until cmax is 
reached (tmax), the velocity of absorption (ka, ta1/2), elimination kinetics (kel, t1/2), and the 
timeframe of presence of effective concentrations in the body. Accuracy of the plasma 
concentration-time curve and of calculated parameters, of course, strongly depends on the 
frequency of sampling.  
For calculation of the absolute oral bioavailability (BVabs) of a substance, AUCpo (after oral 
intake) is related to the AUCiv (after intravenous injection, normalized to the same dose), with 
BVabs = (AUCpo/AUCiv) x 100% (Chen et al., 2005). In contrast, relative oral bioavailability 
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is calculated from orally given doses. The effect of an experimental variant is thereby 
evaluated by comparing the AUCpo measured in the experimental setting to the AUCpo 
measured in a control setting of the experiment, e.g. a different oral formulation. 
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Figure I.3: Model of a plasma concentration-time curve after administration of a single 
oral dose 
AUC, area under the curve; cmax, maximum plasma concentration; tmax, time at maximum plasma 
concentration; t1/2, terminal elimination half-life. 
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I.3.2. BIOAVAILABILITY OF QUERCETIN 
I.3.2.1. Absolute systemic availability 
Data on disappearance from the gut (apparent absorption) are often the only quantitative data 
available from human studies. In a study by Hollman et al. (1995), half of the quercetin 
glycosides from onions disappeared in ileostomized but otherwise healthy volunteers (n = 9) 
until the end of the small intestine and were considered to be absorbed. Furthermore, 
disappearance of 24% quercetin aglycone and 17% rutin (quercetin-3-O-glucorhamnoside) 
have been measured in the same study. Walle et al. (2000) calculated an even higher systemic 
availability of quercetin from quercetin monoglucosides (within the range of 65-81%) in 
ileostomized volunteers (n = 4). It has to be kept in mind, however, that compared to the 
normal situation, an increased number of micro-organisms might have been present at the end 
of the small intestine in ileostomy patients (Graefe et al., 1999). In a human intestinal 
perfusion study (proximal jejunum), ~60% of quercetin-3-O, 4’-O-diglucoside (Q3,4’diG) 
disappeared from an onion and broccoli containing extract (Petri et al., 2003).  
In an isolated rat small intestine perfusion model, quercetin absorption was 38% in the 
jejunum and 19% in the ileum during 90 min of perfusion at a rate of 8 mL min-1 (Spencer & 
Rice-Evans, 2003). In this study, however, mucosal and biliary elimination was not 
considered. Crespy et al. (2003) found bioavailability of quercetin of only 9% in a in situ 
perfusion study on rats, which was the lowest of all flavonoids examined (9-49%). The low 
systemic availability of quercetin was due to a high secretion of conjugated quercetin and 
quercetin derivatives by the liver and intestinal mucosa. First pass elimination was highest for 
quercetin (52% mucosal re-secretion plus 6% biliary secretion) among the flavonoids 
investigated. Absorption of at least 20% of labelled quercetin from the digestive tract was 
deduced from recovery of radioactivity in the bile and urine of rats in an early study (Ueno et 
al., 1983). Recently, however, Graf et al. (2005) found only 6% of an oral quercetin dose (4.9 
mg kg-1 BW) to be absorbed into the systemic circulation of rats, using radioactively labelled 
quercetin-4’-O-glucoside (Q4’G). After applying a dose of 10 mg kg-1 BW to rats, Chen et al. 
(2005) even observed a total bioavailability of 48% for quercetin. In pigs, after intake of 50 
mg quercetin kg-1 BW, Ader et al. (2000) determined a 17% total bioavailability of the 
aglycone in comparison to i.v. application.  
Thus, data on systemic availability of quercetin vary substantially between studies, the 
methods applied, and the species investigated.  
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I.3.2.2. Mechanisms of intestinal absorption 
During the last decade, knowledge about the mechanisms involved in the intestinal absorption 
of flavonols has consistently improved, although several questions still remain open. The 
small intestine is one of the major sites for absorption of dietary flavonols. Thus, quercetin 
monoglucosides are absorbed from the small intestine, as can be deduced from the fast 
appearance (within 30 min) of quercetin derivatives in blood of men and animals after oral 
intake (Cermak et al., 2003; Olthof et al., 2000; Hollman et al., 1997). Quercetin from more 
complex glycosides, like rutin, however, is absorbed from the distal small and the large 
intestine (Morand et al., 2000b). Quercetin itself is a rather lipophilic molecule, which may 
passively diffuse through cell membranes (Walgren et al., 2000a; Movileanu et al., 2000; 
Walgren et al., 1998; Saija et al., 1995). In rats, absorption of quercetin may even occur from 
the stomach (Crespy et al., 2002). In contrast, quercetin glycosides, the predominant form in 
food (chapter I.2.), are relatively polar by nature, and this strongly limits their passive 
transcellular diffusion.  
Enzymatic hydrolysis of quercetin monoglucosides is assumed to take place either in the gut 
lumen (Walle et al., 2000) or, in some cases, intracellularly after uptake into enterocytes. β-
Glycosidic bonds are resistant to hydrolysis by pancreatic enzymes (Arts et al., 2004). An 
intracellular β-glucosidase (CBG, EC 3.2.1.21), however, with a rather broad substrate 
specificity, purified from jejunal cells of rats and both human small intestinal and liver cells, 
can cleave at least some flavonol monoglucosides, e.g. Q4’G, but only weakly affects 
glucosides linked in the 3-position, like quercetin-3-O-glucoside (Q3G) (Day et al., 1998; 
Ioku et al., 1998). Intracellular β-glucosidase has also been found in pig jejunal mucosa 
(McMahon et al., 1997) and liver (Lambert et al., 1999). 
Intracellular cleavage of flavonol monoglucosides requires their mucosal uptake. For 
quercetin monoglucosides, experimental evidence for uptake into enterocytes via the intestinal 
sodium-dependent glucose co-transporter (SGLT1) has been presented (Wolffram et al., 
2002; Ader et al., 2001; Walgren et al., 2000b; Gee et al., 1998). Investigations with everted 
rat jejunal sacs indicated that SGLT1 is capable of transporting quercetin monoglucosides 
(Gee et al., 2000; Gee et al., 1998). This finding was further substantiated by studies using 
human Caco-2 cells (an immortalized human colon cancer cell line), Chinese hamster ovary 
cells (G6D3 cells) stably transfected with SGLT1 (Walgren et al., 2000b), and brush-border 
membrane vesicles from pig jejunum (Cermak et al., 2004). 
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Cleavage of 3-O-linked monoglucosides requires presence of additional β-hydrolases in the 
gut. The brush border membrane (BBM) enzyme lactase-phloridzin hydrolase (LPH, EC 
3.2.1.62) is another mammalian enzyme active against β-glycosidic bonds, cleaving both Q3G 
and Q4’G, but not rutin (Day et al., 2003; Sesink et al., 2003; Németh et al., 2003; Day et al., 
2000b). LPH is located in the BBM of mucosal cells of the small intestine with the active site 
facing the intestinal lumen. The flavonol aglycone, liberated adjacent to the BBM by LPH, is 
assumed to passively diffuse across the BBM (Day et al., 2000b). Stemming from shedded 
epithelial cells, CBG and LPH may also be present in the gut lumen (Walle et al., 2000), but 
Petri et al. (2003) have shown that mucosal enterocytes, rather than luminal contents, are 
responsible for the majority (79-100%) of β-glycosidase activity in human jejunum.  
In some studies evidence has been presented for a minor hydrolysis of dietary flavonol 
glycosides with large interindividual variability in the human oral cavity by both bacteria and 
shedded epithelia cells (Walle et al., 2005; Parisis & Pritchard, 1983). 
Sugar moieties containing rhamnose, for example as present in rutin, seem to sterically hinder 
cleavage of the β-glucosidic bond by endogenous enzymes and, thus, are generally not 
absorbed from the small intestine. Microbial α-rhamnosidase and β-glucosidase are needed to 
release the aglycone from such more complex glycosides (Day & Williamson, 2003; Erlund et 
al., 2000; Crespy et al., 1999) with subsequent absorbtion of quercetin from the distal small 
and the large intestine. Microbial degradation of liberated quercetin, however, may 
concurrently limit its bioavailability (chapter I.3.3.4.) (Cermak et al., 2003; Morand et al., 
2000b).  
Figure I.4 shows a model summarizing potential ways of the intestinal handling of 
polyphenols, which is unrestrictedly valid for flavonols (Scalbert & Williamson, 2000). 
 
I.3.2.3. Metabolism, distribution, and elimination 
Conjugation with glucuronic acid and sulfates are so-called phase II detoxification reactions 
in the metabolism of xenobiotics, rendering a substance more hydrophilic and, in turn, 
accelerating and increasing its renal and/or biliary excretion. Similarly, methylation is an 
inactivating reaction by blocking hydroxyl groups. Sulfation is a major pathway of 
metabolism at low concentrations for many xenobiotics, although this pathway can become 
saturated. Flavonols are to a great extend metabolised already during intestinal absorption 
within the intestinal mucosa and, subsequently, in the liver (first pass). This metabolisation 
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mainly includes O-methylation of hydroxyl groups at the catechol B-ring (catechol-O-
methyltransferase, COMT, EC 2.1.1.6), glucuronidation (uridine-5’-diphosphate 
glucuronosyl-transferase, UGT, EC 2.4.1.17), and sulfation (sulfotransferase, EC 2.8.2.1) 
(Petri et al., 2003; Donovan et al., 2001). 
 
 
 
 
 
Figure I.4: Model for prediction of the absorption of polyphenols in humans based on 
evidence from in vivo and in vitro studies (Scalbert & Williamson, 2000) 
 
 
In blood and urine from humans, at least 23 different metabolites of quercetin have been 
described including mixed sulfates, glucuronides, methylated derivatives and also glucosides 
(Mullen et al., 2004). In rat plasma, more than 18 different flavonol metabolites with varying 
degrees of glucuronidation, methylation and/or sulfation were detected after intake of 
radioactively labelled Q4’G (Graf et al., 2005; Mullen et al., 2002). Intestinal conjugation 
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mechanisms are highly efficient, but statements on activities of the different enzymes 
involved vary. In a rat small intestine perfusion model, Spencer & Rice-Evans (2003) 
observed an almost complete (98%) glucuronidation of quercetin. In an in situ perfusion study 
with quercetin (15 nmol/min) in rats (bile was diverted), Crespy et al. (1999) observed 64% 
as glucuronidated derivatives and methoxylated forms of quercetin, 36% were present as 
sulfated forms, whereas no mixed glucurono-sulfoconjugates were detected in the intestinal 
effluent. Morand et al. (1998) found that in rats, after an adaption period of 3 weeks to a 0.2% 
quercetin-containing diet, the main circulating metabolites were sulfo-glucuronides (91.5%) 
of quercetin and isorhamnetin, whereas only 8.5% where pure quercetin glucuronides. 
Highest activity of UGT for conjugation of quercetin within the intestinal tract of rats has 
been reported for the duodenum (~150 pmol mg protein–1 min–1) in comparison to jejunum 
(~80 pmol mg protein–1 min–1) and stomach (~60 pmol mg protein–1 min–1) (Murota & Terao, 
2005). No value for liver UGT conjugation activity on quercetin was reported in this study. 
An earlier study in rats, however, revealed that UGT activity on (-)epicatechin is higher in the 
mucosa of small and large intestine than in the liver, while highest activity of sulfotransferase 
occurred in liver (Piskula & Terao, 1998a). UGT in microsomes of rat liver were less active 
on quercetin than those of rat intestine (Morand et al., 1998). In humans, UGT activity on 
quercetin in the liver has been observed (Day et al., 2000a), but mRNA of additional 
UGT1A8 and UGT1A10, capable of flavonoid glucuronidation, has been isolated from 
jejunum, ileum, and colon but were not found in liver (Cheng et al., 1999). Furthermore, 
mRNA of UGT1A1 was found to be induced immediately after intake of Q3,4’diG in isolated 
human enterocytes (Petri et al., 2003). In general, after oral intake, the early occurrence of 
conjugated metabolites in plasma observed in different species points towards intensive first 
pass metabolism by the gut mucosa (Erlund et al., 2000; Ader et al., 2000; Morand et al., 
1998). In portal vein blood of pigs only conjugated quercetin was found, supporting the view 
that the small intestine is the major site of conjugation (Cermak et al., 2003). 
Although sulfation of quercetin may occur in intestinal cells, the liver was found to be mainly 
responsible for the formation of sulfo-conjugates of quercetin. Different recombinant human 
sulfotransferases show a high sulfating potential against flavonoids (Pai et al., 2001). It is 
unclear, however, to what extend those enzymes are present in the small intestine. Studies on 
rats indicate that the origin of most circulating sulfated flavonoids is the liver (Donovan et al., 
2001; Piskula & Terao, 1998a), but sulfation has also been observed in the gut mucosa 
(Crespy et al., 1999). Differences between species with respect to tissue distribution and 
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activity of sulfotransferases are likely, as sulfation of xenobiotics in pigs does not seem to 
take place (Caldwell, 1980). 
O-Methylation of quercetin by COMT has been observed both in gut and liver of rats 
(Donovan et al., 2001; Piskula & Terao, 1998a). Also in humans and in pigs, methylated 
metabolites of quercetin have been found after oral application (Hubbard et al., 2003; Cermak 
et al., 2003; Ader et al., 2000; Manach et al., 1998). Main sites of quercetin O-methylation 
are the 3’- and 4’-hydroxyl groups, yielding isorhamnetin or tamarixetin, respectively. 
Differences in the pattern of monomethylated flavonol metabolites have been observed 
between different species (see chapter IV). 
In summary, flavonols undergo ample postabsorptive conjugation reactions within the gut 
mucosa and liver, explaining the absence of free aglyca in plasma in any species investigated 
after oral intake of either free quercetin or quercetin glycosides (Cermak et al., 2003; Day et 
al., 2001; Manach et al., 1999). 
Because quercetin conjugates can be retrieved from the gut lumen of bile-diverted animals 
after perfusion of the intestine with quercetin containing solutions, direct mucosal re-secretion 
of conjugates back into the lumen can be postulated (Crespy et al., 2003; Crespy et al., 1999). 
Apical efflux was indeed identified to be mediated by several transport proteins of the BBM, 
belonging to the family of so-called ATP-binding cassette (ABC) transporters such as the 
multidrug resistance associated protein 2 (MRP2), p-glycoprotein (p-gp) and breast cancer 
restistance protein 1 (BCRP1) (see chapter I.3.3.3.) (Ofer et al., 2005; Sesink et al., 2005; 
Wang et al., 2005). 
Flavonols that leave the enterocytes during intestinal absorption at the basal pole, seem to 
generally enter into blood capillaries and are transported via the portal vein towards the liver 
(Cermak et al., 2003). Murota & Terao (2005) recently reported that quercetin and 
metabolites were additionally found in the lymph of rats (cmax = 3.1 µM, tmax = 30 min) after 
administration of 30 µmol quercetin kg-1 BW. In this study, quercetin was solubilised in 
propylene glycol and after intragastric application, a NaCl solution containing glucose was 
continuously applied. 
A major portion of flavonols are excreted into bile already during the first passage through the 
liver. In rats, ~6% of a perfused amount of quercetin (~14 nmol/min) was found to take this 
route (Crespy et al., 2003). These findings are supported by other bioavailability studies on 
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rats, where also significant amounts of quercetin have been found in bile (Arts et al., 2004; 
Crespy et al., 2002). 
Ueno et al. (1983) reported that more than 30% of quercetin was detected as CO2 72 h after 
intraperitoneal injection of 315 mg kg-1 BW, whereas in bile duct-cannulated rats (secretion 
into the gut lumen via bile is blocked) no exhalation of labelled CO2 was detected. Because 
degradation of quercetin to CO2 is due to bacterial metabolism, this finding exemplifies that 
biliary excretion of quercetin is a major elimination pathway. The amount of flavonoids 
excreted via bile, however, strongly depends on the nature of the flavonoid. Thus, only 1% of 
a perfused dose of catechin (flavanol), was found to be secreted into bile in rats, whereas 
genistein (isoflavone) was extensively secreted (32%) (Crespy et al., 2003). Flavonols and 
their conjugates excreted into the bile or by mucosal mechanisms may partially be re-
absorbed, but eventually reach the large intestine, where they can be hydrolysed by microbial 
enzymes and either are re-absorbed or further degraded (chapter I.3.3.4.).  
Elimination half-life of quercetin after oral intake was observed to be 11-28 h in humans 
(Manach et al., 2005; Graefe et al., 2001; Hollman et al., 1997) in comparison to 3.8 h in pigs 
(Ader et al., 2000), and more than 8 h in rats as derived from (Manach et al., 1997). Walle et 
al. (2001) even found the half-life of radioactively labelled quercetin metabolites (not 
necessarily intact flavonols) in human plasma ranging from 20-72 h. The long half-life would 
favour accumulation in plasma after repeated intake. 
In blood, protein binding of quercetin is more than 98% (Gugler et al., 1975), with albumin 
being the most abundant carrier protein in human blood (~40 mg L-1). In serum, albumin 
major regions for binding are located in subdomains IIA and IIIA, providing hydrophobic 
pockets (He & Carter, 1992). Flavonoids in general display moderate binding affinities for 
albumin, with flavonols and flavones being most tightly bound (Dufour & Dangles, 2005). 
Glycosilation and sulfation, however, lower the affinity of flavonoids to albumin by one order 
of magnitude depending on the conjugation site (Dufour & Dangles, 2005). The slow 
systemic elimination of quercetin in humans might be at least partially explained by its 
particularly high binding affinity to human serum albumin (Dufour & Dangles, 2005; Zsila et 
al., 2003; Manach et al., 1995). Significant differences with respect to affinity and binding 
site were observed for the highly homologous human (HSA) and bovine (BSA) serum 
albumin, and may therefore contribute to different plasma half-lifes in different species 
(Dufour & Dangles, 2005).  
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In humans, elimination of flavonols from the systemic circulation into urine seems to account 
for only a minor portion. Renal excretion of conjugated quercetin after intake of quercetin 
glucosides (50 mg aglycone equivalents) accounts for ~2.5% (0.3-6.4%) of the ingested dose, 
as deduced from 14 bioavailability studies (Manach et al., 2005). Excreted quercetin and 
kaempferol in human urine are mainly in the form of glucuronides (Wang et al., 2003). 
Urinary recovery of other flavonoids, like catechins or isoflavones, is higher than that of 
quercetin in humans (Scalbert & Williamson, 2000). In rats, after i.v. application of quercetin, 
Q3G and rutin, 2.4, 6.7, and 9.2% of the applied dose were retrieved from urine (Choudhury 
et al., 1999). After oral application of a high dose of 14C-quercetin (630 mg kg-1 BW) to bile-
duct cannulated rats, ~9% of the radioactivity was excreted via urine (Ueno et al., 1983). 
Tissue distribution of circulating flavonols has not been thoroughly investigated until now. 
Thus, the ability of flavonols to accumulate within target tissues is so far mainly a matter of 
speculation as data are scarce, even from animal studies. In a pilot study, de Boer et al. (2005) 
have studied the tissue distribution of quercetin in rats (n = 6 per group) and, in a preliminary 
experiment, also in pigs (n = 2). After supplementation of rats with ~50 or 500 mg quercetin 
kg-1 BW d-1 for 11 weeks, the highest flavonol concentration was present in lungs (4.0 and 
15.3 nmol g-1 tissue) and the lowest in brain, white adipose tissue, and spleen. In the pigs, 
supplemented for 3 d with 500 mg quercetin kg-1 BW d-1, the highest concentration was found 
in liver (5.9 nmol g-1) and kidney (2.5 nmol g-1), but no samples from lung tissue were taken 
in this species. Accumulation of flavonols in plasma and heart was lower in pigs than in rats, 
whereas distributions in liver, brain and spleen did not differ. It should be emphasized, 
however, that organ concentrations clearly remain below the plasma concentration of 
quercetin and quercetin derivatives. 
It is assumed that cleavage of glucuronides in target tissues might occur (de Boer et al., 2005; 
O'Leary et al., 2003; O'Leary et al., 2001). Shimoi et al. (2001) suggested that inflammation 
enhances the release of aglyca from glucuronides because β-glucuronidase activity is elevated 
in this situation. Thus, despite the excessive postabsorptive metabolisation of flavonols 
described above, the presence of aglyca in tissues might be conceivable.  
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I.3.3. FACTORS INFLUENCING INTESTINAL ABSORPTION OF QUERCETIN 
Numerous factors may influence the amount of intestinally absorbed quercetin, including the 
type and linkage position of sugar moieties, the vehicle of application, the degree of 
solubilisation, food matrix effects, and food composition (Graefe et al., 2001; Erlund et al., 
2000; Hollman et al., 1999; Hollman et al., 1997). In addition, individual factors such as 
enzyme activities, including polymorphisms, and composition of the intestinal microflora are 
of relevance. These influencing factors are reviewed in this section. 
 
I.3.3.1. Physico-chemical aspects 
Chemical form  
In this context, the pattern of glycosilation is considered as chemical form. In general, 
quercetin monoglucosides, such as Q3G, are better bioavailable than the aglycone and more 
complex glycosides. This was observed in pigs (Cermak et al., 2003; Ader et al., 2000), 
humans (Olthof et al., 2000; Hollman & Katan, 1997; Hollman et al., 1995), and rats (Gee et 
al., 2000; Morand et al., 2000a; Morand et al., 2000b). The higher bioavailability of quercetin 
from monoglucosides is essentially due to the involvement of LPH, which promotes uptake of 
aglyca deriving from monoglucosides (see chapters I.3.2.1. and I.3.3.2.). Furthermore, SGLT1 
may facilitate uptake of quercetin monoglucosides, such as Q3G and Q4’G, across the BBM 
into enterocytes (chapter I.3.2.1.). No aglyca or glycosides other than monoglucosides, 
however, are transported by SGLT1 (Wolffram et al., 2002; Ader et al., 2001; Gee et al., 
1998). More complex flavonol glycosides need microbial cleavage before liberation of the 
aglyca and intestinal uptake (chapter I.3.2.1.). 
Solubility 
The octanol/water partition coefficient Kpart (= P), expressed as log P, is a measure for the 
lipophilicity of a substance and provides information on the efficacy of passive transfer of a 
substance across membranes (Crespy et al., 2003). In general, a positive log P value indicates 
a lipophilic substance and a negative value a hydrophilic substance; log P = 0 indicates an 
equal partition between both phases. According to Brown et al. (1998), log P of quercetin is 
0.08, suggesting an approximately equal distribution between aqueous and lipophilic 
compartments. The coefficients of kaempferol (1.84) and luteolin (1.35) indicate a better 
solubility in the hydrophobic environment, which can be explained by fewer hydroxyl groups 
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of these compounds compared to quercetin. Rothwell et al. (2005) reported log P values for 
quercetin and kaempferol, respectively, of 1.82 and 3.11. Log P values for quercetin and 
kaempferol of 2.74 and 2.69 were calculated by Sergedienė et al. (1999), and of 2.15 and 2.94 
by Crespy et al. (2003). Discrepancies of log P values are most likely attributable to different 
calculation/measurement methods applied. 
In accordance with the more lipophilic nature of quercetin aglycone, Azuma et al. (2002) 
observed, that co-administration of lipids and emulsifiers enhanced the absorption of the 
aglycone. They found an accelerated and enhanced uptake of quercetin in rats when quercetin 
aglycone was administered in water supplemented with 3% (wt/v) emulsifiers (sucrose fatty 
acid ester, polyglycerol fatty acid ester, or sodium taurocholat) and either 10% (wt/wt) 
lecithin or 20% (wt/wt) soybean oil. However, administration with pure lecithin or soybean 
oil in water without additional emulsifiers did not significantly enhance uptake of quercetin. 
In this context, bile constituents, such as sodium taurocholat and phospholipids are considered 
to play an important role in flavonol absorption (Azuma et al., 2002; Piskula & Terao, 
1998b).  
According to Piskula & Terao (1998b), the solubility of quercetin at a dose of 5 mg mL-1 
decreases in a 25% propylene glycol/water (v/v) mixture by almost 3 orders of magnitude and 
in pure water by 5 orders of magnitude as compared to solvation in pure propylene glycol, 
which is in good agreement with results from Azuma et al. (2002). However, no direct 
correlation between the extent of absorption and quercetin´s solubility could be established 
(Piskula, 2000).  
Organic solvents, such as DMSO, propylene glycol, or solutions containing more than 30% 
ethanol, are frequently used vehicles for administration of quercetin in rat studies (Azuma et 
al., 2002; da Silva et al., 1998; Ueno et al., 1983), leading to a higher flavonol absorption 
under experimental conditions (Piskula & Terao, 1998b). Flavanols have also been 
administered complexed with phospholipids to achieve a higher bioavailability (Pietta et al., 
1998). 
 
I.3.3.2. Lactase-phloridzin hydrolase (LPH) 
LPH (EC 3.2.1.62) is a mammalian β-glycosidase present in the BBM of the small intestine 
(chapter I.3.2.1.). The enzyme is mentioned here again because of its pivotal role in the rapid 
in vivo uptake of quercetin from quercetin monoglucosides (Day et al., 2000b). It has become 
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increasingly clear during the last years that LPH is a major determinant for the intestinal 
handling of quercetin monoglucosides (Day et al., 2003; Sesink et al., 2003). For example, in 
a study on in situ perfused rats (jejunum and ileum) after selective inhibition of LPH, a 67% 
reduction of Q3G hydrolysis and, concomitantly, a 75% reduction in quercetin plasma levels 
as compared to rats without LPH inhibition was demonstrated (Sesink et al., 2003).  
LPH is traditionally regarded to be a β-galactosidase necessary for digestion of the 
disaccharide lactose. In in vitro studies with purified LPH from lamb it was confirmed that 
several quercetin glucosides are substrates for this enzyme (Day et al., 2000b). Somewhat 
surprising, it was consistently shown that LPH exerts a low activity against quercetin-3-O-
galactoside (Arts et al., 2004; Németh et al., 2003). Thus, it must be assumed that the spatial 
configuration of the hydroxyl group in the C4-position of the sugar, marking the difference 
between glucose and galactose, is a major determinant for hydrolysis by LPH (Arts et al., 
2004). According to Day et al. (2000b) the flavonols Q3G and Q4’G are substrates for the 
lactase domain and not for the phloridzin hydrolase domaine of LPH, as may have been 
expected due to the flavonoid structure of phloridzin.  
LPH levels vary widely, with 75% of the worlds population showing lactose maldigestion 
caused by physiologically low levels of LPH in adulthood. This may have implications for 
flavonol absorption (Day & Williamson, 2003), although a correlation of quercetin 
bioavailability and LPH activity has not been established yet.  
 
I.3.3.3. Intestinal efflux transporters 
Conjugated flavonol metabolites and flavonol monoglucosides (Q4’G) were found to be 
partly re-secreted into the gut lumen by enterocytes (Walgren et al., 2000a; Crespy et al., 
1999). Apical efflux is mediated by members of the ABC transport protein family present at 
the BBM, such as the multidrug resistance associated protein MRP2, p-glycoprotein (p-gp) 
and breast cancer resistance protein BCRP1 (Ofer et al., 2005; Sesink et al., 2005; Wang et 
al., 2005). These export carriers play a central role in the intestinal defence of organisms 
against toxic compounds. 
In humans, evidence for mucosal re-secretion was presented for the first time in ileostomy 
volunteers (Walle et al., 2000). Subsequently, efflux transporters have been studied in 
different model systems. In rats, luminal efflux of quercetin conjugates out of enterocytes up 
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to 52% of an applied dose was observed, much higher than their biliary secretion (6%) 
(Crespy et al., 2003; Crespy et al., 1999). 
The spectrum of substrates of MRP2 comprises mainly organic anions, like glutathione and 
glucuronic acid conjugates of lipophilic compounds (Borst & Elferink, 2002). During studies 
in Caco-2 cells and Chinese hamster ovary cells (G6D3 cells) stably transfected with SGLT1, 
net uptake of quercetin monoglucosides was only observed after inhibition of MRP2 
(Walgren et al., 2000a; Walgren et al., 2000b). In these studies, transport of Q4’G by MRP2 
was reported for the first time. Tissue distribution of MRP2 is restricted to apical membranes 
of polarized cells and the transporter is mainly expressed in liver, intestine and kidney (van 
Zanden et al., 2005; Walgren et al., 2000a). 
P-glycoprotein is a 170 kDa plasma glycoprotein encoded by human MDR1 gene (Zhou et al., 
2004). It is expressed constitutively in a number of tissues, and is found at high levels on the 
apical surface of epithelial cells in the liver (bile canaliculi), kidney (proximal tubulus), 
pancreas (pancreatic ductal cells), small intestine and colon (columnar mucosal cells), and 
adrenals. Moreover, p-gp is present at the blood-brain barrier, limiting penetration of a 
number of drugs into the brain (Zhou et al., 2004). Similar to MRP2, p-gp is involved in the 
development of drug resistance. The described effects of flavonoids, including quercetin, on 
p-gp function are in part contradictory (Ofer et al., 2005; Wang et al., 2005).  
BCRP1, a transport protein initially discovered in breast cancer cells, has a relatively broad 
tissue distribution and functions similar to MRP2. Expression of BCRP1 in human jejunum is 
comparable with MRP2 (Dietrich et al., 2003). It was recently shown that quercetin aglycone 
and its glucuronide conjugates are substrates for BCRP1 (Sesink et al., 2005). 
 
I.3.3.4. Intestinal microflora 
In humans colonic contents contains ~1010-1012 bacteria g-1 (Day & Williamson, 2003). This 
microflora disposes of a range of enzymes that differ from endogenous enzymes present in the 
gut. The microbes may cleave sulfates, glucuronides and glycosides. Thus, for example, rutin 
and quercetin-3-rhamnoside require microbial enzymes for their deglycosilation. They are 
hydrolysed by strains of colonic Bacteroides distasonis, B. uniformis, and B. ovatus, 
expressing α-rhamnosidase and β-glucosidase (Bokkenheuser et al., 1987). Free aglyca may 
diffuse passively through the gut wall (chapter I.3.2.1.) or are further degraded (see below). 
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In humans, the strictly anaerobic bacterium Eubacterium ramulus occurring at numbers of 
approximately 108 g-1 dry faeces has been identified as one major quercetin degrading micro-
organism, capable of growing on Q3G as the sole carbon and energy source (Braune et al., 
2001). Eubacterium ramulus can degrade a number of flavonoids, including Q3G, quercetin 
and kaempferol, to phenolic acids, being capable of cleaving the flavan ring system in the 
presence of glucose (Blaut et al., 2003). Phenolic metabolites of flavonoids from microbial 
degradation are mainly derivatives of phenylpropionic, phenylacetic and benzoic acids with 
different hydroxylation and methylation patterns (Gonthier et al., 2003). In the case of 
flavonols, relevant degradation products are 3,4-dihydroxybenzoic, 3,4-dihydroxyphenyl-
acetic, and 3-methoxy-4-hydroxybenzoic acid (Aura et al., 2002; Pietta et al., 1997; Merfort 
et al., 1996). Simple phenolic acids may account for 30-60% of the ingested flavonols (Pietta, 
2000). After absorption from the colon, they may contribute to changes in total antioxidant 
capacity of plasma, as some of them still possess a catechol structure (Scalbert & Williamson, 
2000). 
Carbon dioxide (CO2), detected in exhaled air and stemming from microbial degradation of 
quercetin, has been identified to be another major metabolite. In three healthy volunteers, 23-
81% of orally (100 mg) and intravenously (2.5 mg) applied 14C labelled quercetin appeared as 
CO2 (Walle et al., 2001). In intact rats, Ueno et al. (1983) found more than 30% of a high 
dose 14C-quercetin (630 mg kg-1 BW) to be decomposed to CO2 within 24 h after oral 
administration by gavage. 
Although not of direct relevance for flavonols, it is worthy to mention, that microbial 
metabolism may also yield metabolites with an enhanced biological activity compared to the 
parent compound. The most prominent example is the isoflavone daidzein, which is converted 
to equol by the gut flora in ~30-40% of the human population. There is emerging evidence, 
that equol producers demonstrate stronger effects of some biomarkers, such as bone mineral 
density, after isoflavone consumption, compared to non-producers, due to the high estrogenic 
activity of equol as compared to its parent substance daidzein (Setchell et al., 2002). 
Enterohepatic recirculation 
Conjugated flavonols re-enter the small intestine via bile or directly by mucosal re-secretion 
(chapter I.3.2.2.). The secreted conjugates are unlikely to passively diffuse across the 
intestinal wall due to a negative charge at physiological pH (Williamson et al., 2000). In the 
distal ileum and in the colon, however, the conjugates may be subjected to bacterial enzymes. 
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Liberated aglyca may again enter the blood and contribute to plasma levels. This 
enterohepatic recycling could prolong the presence of flavonols within the body. Evidence for 
an enterohepatic recycling of flavonols is mainly based on the occurrence of secondary peaks 
in plasma concentration-time curves at timepoints well after tmax following oral (Crespy et al., 
1999; Manach et al., 1996) or i.v. administration (Ader et al., 2000). 
A recent study on the enterohepatic recirculation of quercetin used surgically ‘linked’ rats. 
The bile from a quercetin-injected (10 mg kg-1 BW) donor rat was cannulated into the 
duodenum of the ‘linked’ recipient rat (Chen et al., 2005). In this study, a major impact of 
enterohepatic recirculation on the bioavailability of quercetin was excluded, because quercetin 
was detected in the portal vein of the recipient rat only at trace amounts 6 h after dosing of 
quercetin-containing bile. After intra-gastric administration of bile containing quercetin 
metabolites (obtained from the donor rat) to a conscious rat, again only trace amounts of 
quercetin were recovered in portal vein blood during an 8 h-experiment. The lack of enteric 
re-absorption of quercetin from biliary quercetin conjugates might be explained by rapid 
degradation of quercetin in the lower intestinal tract. Evidence for rapid metabolism of 
quercetin within the large intestine derives from recent observations on the decomposition of 
quercetin, isorhamnetin and rutin (50 or 100 µmol l-1) using a colon-simulation technique 
(COSITEC) with pig cecal contents (Cermak et al., 2005). Further support for a massive 
degradation of the ring structure of quercetin also derives from the above mentioned fact, that 
up to 80% of an oral quercetin dose was exhaled as CO2 in healthy volunteers (Walle et al., 
2001). 
 
I.3.3.5. Food matrix and food composition 
Different studies investigated the oral bioavailability of quercetin after application of either 
the pure aglycone or glycosides dissolved in various organic solvents (Olthof et al., 2000), in 
water (Erlund et al., 2000), in an encapsulated form (Hollman et al., 1995), mixed among 
meals (Goldberg et al., 2003; Cermak et al., 2003), or as a natural ingredient of food 
(Wiczkowski et al., 2003; Young et al., 1999). 
The presence of food within the gastrointestinal tract (GIT) is known to markedly alter the 
oral absorption of xenobiotic compounds by exerting significant effects on motility, transit 
profiles, pH, blood/lymph flow, secretion, absorption, and intestinal solubilization capacity 
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(Charman et al., 1997). In addition, effects depend, among others, on the dose and chemical 
form of the flavonol, as well as on size and composition of the meal. 
In addition to the presence or absence of food, the applied source of the flavonol seems to 
exert an influence. Within plant material, flavonoids are embedded into the plant matrix, e.g. 
in onion scales or leafy vegetables. During digestion, this matrix is mechanically and 
enzymatically disrupted and the flavonol glycosides are liberated. Some difference in 
bioavailability has been observed when flavonols were administered as pure substances in 
contrast to administration within native food. Much higher plasma concentrations (up to 5 
µM) were achieved when quercetin glucosides were administered to fasted volunteers 
solubilized in a water-alcohol mixture (Olthof et al., 2000) than when an equivalent quantity 
was ingested with food such as onions, apples, or a complex meal (0.3-0.75 nM) (Manach et 
al., 1998; Hollman et al., 1997). Hollman et al. (1997) pointed out, that differences between 
onions and, e.g., apples in cell wall structure, location of glycosides within cells and/or their 
binding to cell constituents may affect liberation of quercetin from these foodstuffs in the 
GIT. Graefe et al. (2001) conducted a four-way crossover study in 12 healthy human 
volunteers to determine the influence of the food matrix on the absorption of quercetin. Each 
subject received an onion supplement or Q4’G (both equivalent to 100 mg quercetin), as well 
as rutin and buckwheat tea (both equivalent to 200 mg quercetin). There was no significant 
difference in the bioavailability and pharmacokinetic parameters between the onion 
supplement or Q4’G. Peak concentrations were reached 4.3 ± 1.8 h after administration of 
buckwheat tea and 7.0 ± 2.9 h after ingestion of rutin. To a minor extend, the plant matrix 
influences both the rate and extend of absorption in the case of buckwheat tea administration 
compared with the isolated compound. 
In addition to the food matrix, the composition of a meal may affect the bioavailability of 
flavonoids. In this context, influences of alcohol and of the macronutrients fat, protein and 
also carbohydrates have been proposed. 
Ethanol from beverages such as wine may aid in extracting the flavonoids from the chyme 
and act as a permeation enhancer. The findings of Goldberg et al. (2003) supported this 
theory, as they observed higher quercetin plasma levels in humans when the same amount of 
quercetin (422 nmol kg-1 BW) was administered dissolved in white wine with 11.5% alcohol 
content (cmax = 127 µg quercetin L-1 serum), in comparison to administration of quercetin 
dissolved in white grape juice (cmax = 63 µg L-1) or vegetable juice (cmax = 47 µg L-1). Azuma 
et al. (2002) also found an enhancing effect of ethanol on the bioavailability of quercetin (150 
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µmol kg-1 BW) in rats, but significant effects of ethanol were only observed at rather high 
doses of alcohol (at least 30%, v/v). In contrast to these results, a study by de Vries et al. 
(2001) on quercetin bioavailability (14-16 mg) from native food reported that the alcoholic 
beverage red wine in comparison to a portion of onions or a glass of tea is a poor source of 
flavonols, especially of quercetin, in humans. 
Tea is another major source of flavonoids. It was speculated that the addition of milk to a tea 
infusion may inhibit absorption of tea flavonoids due to binding of polyphenols to proteins 
(Serafini et al., 1996). It was convincingly demonstrated, however, that addition of milk does 
not affect the absorption of flavonoids from tea in man (Hollman et al., 2001; Het Hof et al., 
1998). In another study on the bioavailability of polyphenols, the authors observed a decrease 
in (-)epicatechin (flavanol) from dark chocolate consumed with 200 mL milk or when the 
same amount of (-)epicatechin was ingested with milk chocolate, in comparison to dark 
chocolate. They suggested that the reduced bioavailability could be due to interactions 
between chocolate flavonoids and milk proteins, thus reducing the absorption of catechins 
(Serafini et al., 2003). Association of quercetin with protein deriving from food, especially 
soy and whey protein, in chyme has been proofed in vitro (Rawel et al., 2002; Kroll et al., 
2002). For quercetin, primarily the hydroxyl groups on the ring B and C can react with lysine 
and tryptophane in proteins by forming covalent bonds (Rawel et al., 2002; Kroll et al., 
2002). 
Some studies indicate that the presence of lipids and emulsifying agents may improve the 
absorption of specific flavonoids. For example, catechins from green tea (Pietta et al., 1998), 
oligomeric proanthocyanidins from grape seeds, and silibinin from milk thistle are absorbed 
to a higher extent when administered as phospholipid complexes rather than in the free form 
(Pietta, 2000). Azuma et al. (2002) suggested, that incorporation of quercetin into lipid 
micelles was an important factor for a higher absorption of quercetin. The effect of co-
ingested lipids and emulsifiers on the accumulation of quercetin metabolites in blood plasma 
after short-term ingestion of onions by rats were investigated (Azuma et al., 2003). More than 
4.6% (wt/wt) of soybean oil in the diets significantly enhanced the accumulation of quercetin 
metabolites in the plasma. Co-administration of fish oil or beef tallow showed effects 
comparable to that of soybean oil at concentrations of 9.5% (wt/wt), and lecithin was more 
effective than the other three lipids. The addition of emulsifiers, sodium caseinate and sucrose 
fatty acid ester, to the drinking water while administering soybean oil containing diet was able 
to again enhance bioavailability of quercetin significantly. These results indicate that co-
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ingested lipids and emulsifiers could enhance the bioavailability of quercetin glucosides in 
onion. 
No effect of varying amounts of cornstarch on quercetin bioavailability was observed in 
preliminary trials (Azuma et al., 2003). In contrast, Schramm et al. (2003) observed that co-
administration of sugar and bread test meals increased the bioavailability of cacao flavonols. 
In this study no effects on the pharmacokinetics of quercetin by protein rich test meals were 
observed and the co-administration of butter only non-significantly enhanced the systemic 
availability of quercetin. 
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ABSTRACT 
The flavonol quercetin is one of the most prevalent flavonoids found in edible plants. In this 
study, the influence of dietary fat on oral bioavailability of quercetin was investigated. 
Quercetin (30 µmol/kg body weight) was administered either as the lipophilic aglycone or as 
the more hydrophilic quercetin-3-O-glucoside in test meals differing in fat content (3, 17 or 
32 g fat/100g diet) to growing pigs. Blood samples were drawn repeatedly over a 24-h period 
and analyzed by HPLC. The main metabolite found in plasma was always conjugated 
quercetin. Quercetin bioavailability from each diet was always higher from the glucoside than 
from the aglycone. Irrespective of the chemical form applied, the bioavailability of quercetin 
was higher in the 17% fat diet compared with the 3% fat diet (P < 0.05). No further effect on 
bioavailability was observed when the flavonols were administered with diets containing 32% 
fat. The elimination of quercetin was significantly delayed after its application with fat-
enriched diets (P < 0.05). Thus, in addition to the chemical form of the flavonol, the fat 
content of the diet influences oral bioavailability of quercetin. 
Key words: flavonoids, bioavailability, quercetin, fat, pigs 
 
 
INTRODUCTION 
The flavonol quercetin is one of the most prevalent flavonoids found in edible plants. In 
plants and subsequently in plant-derived foods, quercetin is present mainly as glycosides 
(1,2). It has been shown repeatedly that the sugar moiety is a major determinant governing the 
intestinal absorption of quercetin (3-6). In addition to the chemical form of the flavonol, the 
applied vehicle or the composition of the diet seems to have a substantial effect on quercetin 
bioavailability (7-10). In a previous study by our group, the bioavailability of quercetin from 
quercetin-3-O-glucoside (Q3G)4 was significantly enhanced when Q3G was administered to 
pigs in a meal rich in fat and low in carbohydrates, compared with a standard carbohydrate-
rich pig diet (3). One reason for this finding could have been the difference in fat 
concentration in the experimental diets because lipids in combination with emulsifiers were 
                                                 
4Abbreviations used: AUC, area under the curve; BBM, brush border membrane; BW, body weight; c480, c720, 
plasma concentration at 480 or 720 min after ingestion of test meal, respectively; cmax, maximal plasma 
concentration; LPH, lactase-phlorizin hydrolase; LSM, least-squares means; Q3G, quercetin-3-O-glucoside; 
SGLT1, sodium-dependent glucose transporter; tmax, time at maximal plasma concentration. 
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shown to enhance the absorption of orally administered quercetin in rats (8). Therefore, in this 
study we investigated the effect of the dietary fat content on the oral bioavailability of 
quercetin in pigs. Quercetin was administered either as the rather lipophilic aglycone or as the 
more water-soluble Q3G in diets with differing fat contents.  
 
 
MATERIALS AND METHODS 
Animals, diets and experimental procedure 
Cross-bred growing male castrated pigs (n = 7) with a body weight (BW) of 30-35 kg were 
purchased from a local farmer. The pigs were surgically equipped with permanent catheters 
(Cook Deutschland GmbH) placed in the jugular vein. They were restrictively fed (80% of 
voluntary feed intake) a commercial pig diet composed of barley, wheat and defatted soybean 
meal (Plambeck Kraftfutter). The composition of this diet (designated as 3% fat diet) is shown 
in Table II.1. Vitamins and minerals were supplemented according to the recommendations of 
the German Society of Nutritional Physiology (11). Water was freely available by nipple 
drinkers. 
Each pig received in consecutive experiments either quercetin aglycone or Q3G (30 µmol/kg 
BW) mixed into a test meal directly before administration. The test meals consisted either of 
the regular pig diet (3% fat diet) or of an isoenergetic amount of the same diet enriched with 
either 15 or 30 g lard/100 g (wt/wt) (designated as the 17 and 32% fat diets, respectively) 
(Table II.1). Lard was obtained from Fischermanns GmbH. Blood samples (8 mL each) were 
collected over a period of 24 h. After each experiment, there was a wash-out period of 24 h.  
 
Processing of plasma samples and HPLC analysis 
Blood samples were drawn into heparinized containers, immediately centrifuged (1500 x g, 
10 min, 4°C) and stored at –70°C until analysis by HPLC as described previously (3,12,13). 
All samples were treated enzymatically with β-glucuronidase/sulfatase before the extraction 
of flavonol compounds.  
All flavonols were obtained from Carl Roth GmbH. β-Glucuronidase/sulfatase type H-2 
(crude enzyme extract from Helix pomatia) was purchased from Sigma-Aldrich AG. 
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Table II.1: Composition of the diets1 
 % fat in the diet 
Component 3 17 32 
 g/kg diet 
Dry matter 869.2 888.8 914.2 
Crude fat 32.9 174.1 318.2 
Crude protein 161.8 142.4 115.6 
Ash-free NDF2 120.5 109.6 86.6 
NFC3 500.1 419.0 353.2 
Starch 399.1 347.3 292.0 
 MJ/kg diet 
Gross energy 16.2 19.6 22.7 
1Isoenergetic amounts of each diet were fed: 200.0 g of the 3% fat diet, 162.0 g of the 17% fat 
diet, and 136.2 g of the 32% fat diet. 
2NDF, neutral detergent fiber. 
3NFC, nonfiber carbohydrates. 
 
 
Statistical analysis 
The area under the plasma concentration-time curve (AUC) was determined according to the 
linear trapezoidal rule. For each pig and treatment, total bioavailability (AUCtotal) was 
calculated by adding up the AUC values of quercetin and its metabolites with an intact 
flavonol structure (isorhamnetin and tamarixetin). AUC data, maximal plasma concentrations 
(cmax), those at 480 (c480) and 720 min (c720) after ingestion of the test meal, and time at 
maximal plasma concentration (tmax) values were analyzed with the MIXED model procedure 
from SAS (Version 8.2, SAS Institute) based on the model: Yi,j,k= µ + Di + Fj + (D x F)i,j + 
Ak + ei,j,k where µ = mean, Di = diet (i = 3, 17, or 32% fat diet), Fj = administered flavonol (j = 
quercetin aglycone or Q3G), (D x F) = diet x administered flavonol interaction, Ak = animal, 
and ei,j,k = residual error. The individual pig was treated as random factor. AUC data, cmax, 
c480, c720 and tmax values are presented as least-squares means (LSM) ± SEM. A P-value 
< 0.05 was considered significant. 
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RESULTS 
Irrespective of the administered flavonol or the diet fed, the main metabolite in plasma after 
β-glucuronidase/sulfatase treatment of the samples was always quercetin (78.8 ± 0.8%, 
n = 38). In addition to quercetin, the monomethylated derivatives isorhamnetin (3’-O-
methyl quercetin, 11.0 ± 0.5%) and tamarixetin (4’-O-methyl quercetin, 10.3 ± 0.4%) were 
found. No differences in the relative abundance of these metabolites were observed after 
intake of the aglycone or of the glucoside. 
After the intake of quercetin aglycone with the 3% fat diet, the mean peak plasma 
concentration (cmax) was reached ~100 min (tmax) after intake (Table II.2). When the flavonol 
was administered together with the 17 or 32% fat diets, plasma concentrations of quercetin 
rose more sharply (Figure II.1) and reached their peak levels significantly earlier (Table II.2). 
Thereafter, quercetin levels with the 3% fat diet decreased continuously until they were below 
the detection limit after 24 h (Figure II.1). The elimination of quercetin was clearly delayed 
after its application with the fat-enriched diets; 480 min after intake (c480) with the 32% fat 
diet, the quercetin plasma concentration (0.054 ± 0.011 µmol/L, n = 7) was higher than the 
value obtained with the 3% fat diet (0.015 ± 0.011 µmol/L, n = 7, P < 0.05). However, the 
respective plasma concentration obtained with the 17% fat diet (0.050 ± 0.013 µmol/L, n = 6) 
did not differ from 3% fat diet value (P = 0.07) or 32% fat diet value (P = 0.81). The values 
determined at 720 min after intake (c720) with the 17 and 32% fat diets (0.073 ± 0.016 µmol/L 
and 0.070 ± 0.015 µmol/L, respectively) were both significantly higher than the 
corresponding value attained after intake with the 3% fat diet (0.015 ± 0.015 µmol/L, 
P < 0.05) (Figure II.1). The fat content of the diet had a significant effect on total 
bioavailability (AUCtotal) of quercetin from the aglycone-containing diets (Table II.2). 
Compared with the 3% fat diet, bioavailability was significantly increased with the fat-
enriched diets, with no significant difference between the 17 and 32% fat diets. 
After intake of Q3G with the 3% fat diet, the mean peak plasma concentration of quercetin 
was reached after ~70 min (Table II.2). When the flavonol glucoside was administered 
together with fat-enriched diets, the plasma concentrations of quercetin reached their peak 
levels earlier, which was significant only for the 32% fat diet. However, the cmax value of 
plasma quercetin was lowest after intake with 32% fat (Table II.2). Similar to what was 
observed with the diets containing the aglycone, the elimination of quercetin was delayed 
with the fat-enriched diets (inset Figure II.1). Plasma concentrations after 480 min differed 
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significantly among all 3 diets (0.053 ± 0.020 µmol/L in the 3% fat diet, 0.123 ± 0.020 
µmol/L in the 17% fat diet, P < 0.05 vs. 3% fat diet, and 0.174 ± 0.020 µmol/L in the 32% fat 
diet, P < 0.05 vs. 3% and vs. 17% fat diet, n = 6). The c720 values from both the 17 and 32% 
fat diets (0.071 ± 0.015 µmol/L and 0.090 ± 0.020 µmol/L, respectively) were also 
significantly higher than the plasma concentration after intake with the 3% fat diet (0.026 
± 0.015 µmol/L, P < 0.05). Hence, the fat content of the diet had a significant effect on 
AUCtotal from Q3G (Table II.2). 
 
Table II.2: Relative bioavailability and pharmacokinetic parameters of quercetin in pigs after 
intake of quercetin aglycone or quercetin-3-O-glucoside in test meals differing in their fat 
content1 
 
Diet cmax2  tmax3  AUCtotal4 Relative  bioavailability5 
Quercetin aglycone 
% fat µmol/L min min x µmol/L % 
3 0.518 ± 0.056 a 102.9 ± 8.0 a 117.3 ± 18.5 b 100 
17 0.583 ± 0.060 a 70.0 ± 8.6 b 184.5 ± 19.8 a 157 
32 0.563 ± 0.056 a 51.4 ± 8.0 b 176.0 ± 18.5 a 150 
Quercetin-3-O-glucoside 
% fat µmol/L min min x µmol/L % 
3 0.906 ± 0.089 a 70.0 ± 7.9 a 205.5 ± 19.8 b 100 
17 0.895 ± 0.089 a   50.0 ± 7.9 a,b 270.9 ± 19.8 a 132 
32 0.642 ± 0.089 b 45.0 ± 7.9 b 249.7 ± 19.8 a 122 
 
1For composition of the diets, see Table II.1; values are LSM ± SEM, n = 6; for quercetin aglycone 
in the 3 and 32% fat diets, n = 7. Means in a column not sharing a superscript letter within the 
quercetin aglycone group or within the quercetin-3-O-glucoside group differ, P < 0.05. 
2cmax, maximum plasma concentration of quercetin. 
3tmax, time between administration of test meal and the appearance of cmax. 
4AUCtotal, area under the plasma concentation-time curve from 0 to 24 h for the sum of quercetin 
and its metabolites (isorhamnetin and tamarixetin). 
5Relative bioavailability within the quercetin aglycone group or within the quercetin-3-O-glucoside 
group. 
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In the case of Q3G intake, the significantly increased AUCtotal values obtained with the fat-
enriched diets were due solely to the delayed elimination of quercetin (inset Figure II.1). 
The amount of quercetin and methylated quercetin metabolites in the systemic circulation was 
also significantly influenced by the chemical form of quercetin administered. With quercetin 
aglycone, the mean total bioavailability from any of the diets was always significantly lower 
than from the respective diets containing the quercetin glucoside (P < 0.05) (Table II.2). 
The fat content of the diet and the chemical form of the flavonol, however, did not have a 
significant interaction. 
 
 
 
Figure II.1: Plasma concentration-time curves of quercetin after oral administration of 
quercetin aglycone or of quercetin-3-O-glucoside (inset) to pigs (30 µmol/kg BW each) in 
test meals that differed in their fat content 
Filled circles represent values for 3% fat diet, open triangles for the 17% fat diet, and open squares 
for the 32% fat diet (w/w). Data are means ± SEM (n = 6; for quercetin aglycone in the 3 and 32% fat 
diets, n = 7).  
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DISCUSSION 
In a recent experiment, total oral bioavailability of quercetin in pigs was increased by 140% 
when Q3G was administered with meat compared with a standard pig diet (3). One possible 
explanation for this finding could have been the higher fat concentration of meat. We 
therefore conducted the present study to investigate the influence of the dietary fat content on 
the oral bioavailability of quercetin from both quercetin aglycone and Q3G.  
In pig plasma, quercetin and its metabolites with a flavonol structure are present in substantial 
amounts only as conjugates (3,12). Therefore, we treated all plasma samples with 
β-glucuronidase/sulfatase to release the flavonol aglycones. 
In all experiments, quercetin was found in plasma within 30 min after ingestion. This suggests 
that absorption had already occured in the upper small intestine, irrespective of the diet and of 
the flavonol administered. 
The increase in the dietary fat content from 3 to 17% crude fat enhanced the total 
bioavailability of quercetin (quercetin and its metabolites, isorhamnetin and tamarixetin) from 
the quercetin aglycone containing diet by ~50%. This effect was already maximal because a 
further increase in dietary fat had no additional effect. It is generally believed that the rather 
lipophilic quercetin aglycone diffuses passively through the brush border membrane (BBM) 
of enterocytes (14,15). Azuma et al. (8) observed that coadministration of lipids (soybean oil 
or lecithin) and emulsifiers such as the bile constituent taurocholate was able to enhance and 
accelerate the intestinal absorption of quercetin in rats. In another rat study, the absorption of 
the flavanol catechin was enhanced when green tea catechins were administered as a 
phospholipid complex rather than as free catechins (16). Thus, it is likely that in the presence 
of dietary fat, quercetin was partly incorporated into mixed bile salt micelles in the lumen of 
the duodenum. This could have promoted its solubility and transport through the unstirred 
water layer and passive diffusion through the BBM. 
Interestingly, an enhancing effect of dietary fat on total bioavailability of quercetin was also 
found after administration of Q3G-containing diets. At first glance, this was an unexpected 
observation, because the more hydrophilic glucoside of quercetin should not directly interact 
with the absorption of lipids. In agreement with this finding, Azuma et al. (17) recently 
observed an enhancement of quercetin bioavailability from quercetin glucosides in onions by 
administration with at least 4.6% fat. In the present study, the effect of dietary fat on quercetin 
bioavailability from Q3G was due exclusively to a delayed elimination of quercetin from 
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plasma. In contrast, the addition of fat to the quercetin aglycone-containing diets also 
enhanced the absorption of the flavonol. Several studies pointed to the involvement of 
β-glycosidases such as the BBM enzyme, lactase-phlorizin hydrolase (LPH, EC 3.2.1.62), in 
the intestinal absorption of Q3G (18-20). According to those studies, Q3G is hydrolyzed by 
LPH in the small intestine and the liberated aglycone diffuses passively across the BBM into 
the enterocyte. Because the liberation of quercetin from Q3G by LPH occurs adjacent to the 
BBM, enhanced solubility and diffusion through the unstirred water layer as promoted by the 
formation of micelles cannot be expected in this case. However, an enhancing effect of 
dietary fat on the reabsorption of quercetin during enterohepatic circulation can be expected 
after the administration of both Q3G and quercetin aglycone. Stimulation of biliary secretion 
by dietary fat intensifies excretion of quercetin glucuronides and/or sulfates with the bile (21). 
After microbial deconjugation of the excreted conjugates in the lower small and large 
intestine, quercetin could be partially re-absorbed (22). This could explain the higher plasma 
concentrations of quercetin several hours after ingestion with the fat-enriched diets. 
The earlier appearance of maximal quercetin plasma concentrations after ingestion with fat 
could be explained by a partial incorporation of the quercetin conjugates formed in the 
enterocyte into chylomicrons with consecutive export into the peripheral blood via lymph. 
Thus, part of the quercetin would bypass the liver and, consequently, increase the plasma 
concentration. However, because no data are available concerning the incorporation of 
quercetin conjugates into lipoproteins during absorption, this remains speculative at present. 
In our previous study, administration of Q3G together with meat enhanced total quercetin 
bioavailability by 140% (3), whereas the addition of fat in the present study enhanced 
bioavailability of Q3G by only ~30%. This suggests that other dietary factors in addition to 
fat influence the bioavailability of quercetin. It is conceivable that the lack of carbohydrates in 
the meat could have favored carrier-mediated uptake of Q3G by the intestinal sodium-
dependent glucose transporter (SGLT1) (3). Unspecific binding to food components such as 
soy protein could have limited the absorption of quercetin from the test meal used compared 
with the meat meal (23). In this regard, it is important to note that the absolute amount of 
protein in the meat meal was only ~10% of that in the standard meal used (3).  
In the present study, all test meals were isoenergetic to avoid differences in the rate of 
stomach emptying, which in turn would influence absorption kinetics. Hence, the test meals 
differed inevitably in protein (32, 23, and 16 g crude protein) and carbohydrate content (100, 
68, and 48 g nonfiber carbohydrates) in the 3, 17, and 32% fat test meals, respectively. These 
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differences in protein and carbohydrate content were rather small, however, compared with 
the relative differences in fat content (7, 28, and 43 g crude fat in the 3, 17, and 32% fat test 
meals, respectively). Thus, in our opinion it is most likely that the differences in the fat 
content were responsible for the observed effects on quercetin bioavailability.  
Regardless of these latter considerations, Q3G was always more bioavailable than quercetin 
aglycone with each of the different diets. This observation agrees with our previous study 
using pigs (3), and is also known from studies on humans (7) and rats (24). Most authors 
explain the higher bioavailability of Q3G compared with the aglycone by the occurrence of 
higher local quercetin concentrations adjacent to the BBM due to the Q3G-hydrolyzing 
activity of LPH (see above). In addition, transport of Q3G by SGLT1 could also contribute to 
the higher bioavailability of quercetin from Q3G compared with quercetin aglycone. Several 
studies showed an interaction of Q3G with SGLT1 (5,25,26). A recent study demonstrated 
transport of a quercetin glucoside by SGLT1 (27). In experiments with pig small intestine 
BBM vesicles, we also found evidence for transport of Q3G by SGLT1 (28). 
In summary, we showed that the dietary fat content influences the bioavailability of quercetin. 
Bioavailability from both quercetin aglycone and quercetin-3-O-glucoside is enhanced in a 
diet enriched with fat compared with a low-fat diet. This could be explained by an improved 
solubility and an accelerated absorption of the lipophilic quercetin aglycone via lipid micelles 
and a prolonged enterohepatic circulation.  
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ABSTRACT 
In a previous study, we have shown that the dietary fat content influences the bioavailability 
of the flavonol quercetin. In this study, the influence of the fatty acid pattern of dietary fats on 
oral bioavailability of quercetin was investigated. Quercetin (30 µmol/kg body weight) was 
administered to growing pigs (n = 6) in test meals consisting either of 200 g of a standard pig 
diet (2% crude fat) or of the same diet supplemented with 15 g fat/100 g diet using either 
medium-chain (MCT) or long-chain fatty acid triacylglycerols (LCT). Blood samples were 
drawn repeatedly over a period of 24 hours and analysed by HPLC. In addition, the influence 
of the different diets on gastric emptying was investigated in rats. In pigs, the bioavailability 
of quercetin was measured by quantifying its plasma metabolites with an intact flavonol 
structure. Bioavailability was enhanced by 38% (P<0·05) and 12% (P>0·05) after intake with 
the MCT and LCT diets, respectively, compared to standard diet. Maximum plasma 
concentrations of quercetin were reached significantly later with the MCT diet in comparison 
to the LCT or standard diet (P<0·05). No differences in dry matter of gastric content were 
observed 60 min after intake of the experimental diets in rats. 
Thus, administration of quercetin together with a diet containing MCT fat enhances the 
bioavailability of the flavonol. Interestingly, absorption of quercetin was significantly delayed 
with this particular diet. However, this was probably not due to a slower gastric emptying of 
the MCT diet. 
Key words: Quercetin: Bioavailability: Fat: Pig 
 
 
INTRODUCTION 
Flavonoids are polyphenolic secondary metabolites that occur ubiquitously in higher plants. 
Their abundance in the human diet has raised an increasing interest in their bioavailability and 
biological properties. Flavonoids exert several biological activities, which are mainly related 
to their ability to influence various enzymes and/or to their antioxidant properties (Middleton 
et al. 2000). Detailed assessment of the bioavailability of putatively beneficial polyphenolic 
food constituents is vital for the evaluation of health effects in man and animals (Manach et 
al. 2005). The flavonol quercetin is one of the major representatives of flavonoids in many 
edible plants (Herrmann 1988; Hertog et al. 1992) and also one of the most studied. 
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In a previous study of our group conducted in pigs, oral bioavailability of quercetin aglycone 
from a test meal was enhanced by 57% by the addition of 15% fat (wt/wt) to a low-fat 
standard pig diet (Lesser et al. 2004). We speculated whether the enhancement of quercetin 
bioavailability was due to a better solubility of the relatively lipophilic quercetin aglycone in 
the intestinal tract in the presence of fat (Azuma et al. 2002). In this case, an increased 
absorption from fat containing diets should be largely independent of the type of dietary fat. 
Another possible explanation could be the generation of chylomicrons in the intestinal 
mucosa. Dietary fat mainly comprises triacylglycerols with long-chain fatty acids (chain 
length >C12). After luminal hydrolysis, mucosal uptake and resynthesis of triacylglycerols, 
long-chain fatty acid triacylglycerols (LCT4) are incorporated into chylomicrons and are 
consecutively transported via lymph. In contrast, medium-chain fatty acid triacylglycerols 
(MCT, chain length C8-C12) are hydrolysed and predominantly exported from the enterocytes 
as NEFA into the mesenterical blood; they reach the liver via the portal vein (Bloom et al. 
1951; Hashim et al. 1964; for review: Harkins & Sarett 1968). Transport together with LCT 
within chylomicrons via the lymphatic vessels (Murota & Terao 2005) could enhance 
quercetin bioavailability due to bypassing of the liver, and, thereby, reduce biliary elimination 
during the first liver passage (first pass effect). If this was true, mainly fats containing LCT 
should increase the bioavailability of flavonols but not fats comprised of MCT due to the 
different handling of LCT and MCT during intestinal absorption (Harkins & Sarett 1968). In 
order to differentiate between these two possibilities, i.e. better solubility vs. bypassing of the 
liver, we fed quercetin (30 µmol/kg BW) to pigs with test meals consisting of a low-fat pig 
diet (standard diet), or of the same diet enriched with either 15 g MCT or LCT fat/100 g diet, 
respectively. Although quercetin is present mainly in glycosidic form in the diet, hydrolysis of 
quercetin glycosides by the brush border membrane enzyme lactase-phloridzin hydrolase or 
by cytosolic β-glycosidase is a prerequisite for its absorption in the small intestine (Manach & 
Donovan 2004). Thus, further biotransformation of the released aglycone and export of the 
formed quercetin metabolites into the blood or intestinal lymph should be independent of the 
quercetin source. The aglycone is more lipophilic than its glucosides and, thus, better soluble 
in the presence of dietary fat. For these reasons, we chose to use quercetin aglycone in our 
study instead of quercetin glycosides. 
                                                 
4Abbreviations: AUC, area under the curve; BW, body weight; CCK, cholecystokinin, cmax, maximum plasma 
concentration; LCT, long-chain fatty acid triacylglycerols; MCT, medium-chain fatty acid triacylglycerols; tmax, 
time at maximum plasma concentration. 
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MATERIALS AND METHODS 
Animals and diets 
Cross-bred growing male castrated pigs (n = 6) with a body weight (BW) of 30-35 kg were 
purchased from a local farmer. The pigs were surgically equipped with permanent catheters 
(Cook Deutschland GmbH, Mönchengladbach, D) placed in the left jugular vein. The pigs 
were restrictively fed (80% of voluntary feed intake) with a commercial pig diet composed 
mainly of wheat, barley, and defatted soybean meal (Plambeck Kraftfutter, Brügge, D). The 
composition of this diet (designated as standard diet) is shown in Table III.1. 
 
 
Table III.1: Composition of diets* 
 Diets 
Components Standard LCT MCT 
 g/kg diet 
Dry matter 857·2 882·7 881·4 
Crude fat 16·7 159·2 162·8§ 
Crude protein 172·3 140·5 144·8 
Ash-free NDF 147·3 176·6 124·6 
NFC 468·6 360·6 407·6 
Starch 426·1 365·2 369·6 
 MJ/kg diet 
Gross energy 15·6 19·0 19·1 
 
LCT, long-chain fatty acid triacylglycerols; MCT, medium-chain fatty acid triacylglycerols; NDF, neutral 
deterent fiber; NFC, nonfiber carbohydrates. 
*Isoenergetic amounts of each diet were fed: 200 g of the standard diet, and 162 g of LCT and MCT 
diets, each. 
§Comprised of 90% MCT and 10% LCT. 
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Test meals were isoenergetic and consisted of the standard diet or of the same diet enriched 
with either 15 g lard or MCT oil/100 g diet (wt/wt; designated as LCT or MCT diet, 
respectively) (Table III.1). The fatty acids of the MCT oil consisted solely of octanoic and 
decanoic acid with a mean chain length of C8·8. The lard was composed of LCT with a mean 
chain length of C17·3, as determined by saponification number. Predominant fatty acids in lard 
are C18:1 (43 g/100 g), C16:0 (24 g/100 g), C18:0 (14 g/100 g) and C18:2 (9 g/100 g), with 
no fatty acids of less than 14 carbon atoms (Belitz & Grosch 1992). Commercial lard was 
obtained from Fischermanns GmbH (Duisburg, D), and the MCT oil was a kind gift from 
Unilever (Vlaardingen, NL). Vitamins and minerals where supplemented according to the 
recommendations of the German Society of Nutritional Physiology (Ausschuss für 
Bedarfsnormen der Gesellschaft für Ernährungsphysiologie 1987). Water was supplied for ad 
libitum intake by nipple drinkers. 
Additionally, 18 male CD rats (Charles River, Sulzfeld, D) with a mean BW of approximately 
250 g were used for an experiment aimed to investigate gastric emptying after consumption of 
the specific diets. The rats were housed individually and kept on a 12 h light/dark cycle. They 
were accustomed to eating the standard pig diet for one week prior to the experiment.  
The experiments were approved by the Animal Welfare Officer of the University of Kiel and 
by the relevant legal authorities (Ministry of Agriculture and Environment of Schleswig-
Holstein). 
 
Experimental procedure – bioavailability in pigs 
Each pig received a dose of 30 µmol quercetin/kg BW mixed into the test meal directly before 
feeding. Thereby, each of the three different quercetin containing diets was administered in 
consecutive experiments to each pig. Test meals were isoenergetic. Fifteen blood samples (8 
mL each) were collected from each pig over a period of 24 h after intake of each test meal. 
After every experiment, there was a wash-out period of 24 h.  
 
Experimental procedure – gastric emptying in rats 
Two days prior to the experiment, the rats were allocated to three groups (n = 6 per group) 
and trained to eat meals of 5 g of the respective test diets (standard, LCT, or MCT) within 
15 min at beginning and end of the dark period. The BW did not differ between the groups 
(253·4 (SEM 5·0), 256·3 (SEM 6·3), and 254·5 (SEM 4·5) g for the standard, LCT, and MCT 
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group, respectively). After fasting for 11 h (water allowed), the rats were fed the respective 
test meals containing 0·5 mmol quercetin/100 g diet (equimolar to the concentration in the 
standard diet pig test meal). The rats were anaesthetized with CO2 1 h after intake of the 
meals and immediately decapitated. Blood was collected, the abdominal cavity was opened, 
the stomach was proximally and distally ligated and removed. Stomach content was collected 
by rinsing the stomach with 2 mL of pure water. The gastric content was dried (106 °C) until 
weight constancy. Dry matter was related to the dry matter of the respective diet ingested. 
 
Processing of plasma samples and HPLC analysis 
Blood samples from pigs and rats were drawn into heparinized containers and immediately 
centrifuged (1500 x g, 10 min, 4 °C). Plasma was stored at –70 °C until analysis by HPLC as 
described previously (Hollman et al. 1996; Ader et al. 2000). By the sensitive HPLC 
postcolumn chelation method applied, only flavonols possessing an intact ring structure with 
a free 3-OH group are detected (here: quercetin, isorhamnetin, and tamarixetin). Therefore, all 
plasma samples were treated enzymatically with β-glucuronidase/sulfatase (type H-2, crude 
enzyme extract from Helix pomatia, Sigma-Aldrich AG, Taufkirchen, D) before the 
extraction of flavonol compounds. All flavonols were obtained from Carl Roth GmbH 
(Karlsruhe, D). 
 
Statistical analyses 
Data are presented as mean values ± SEM. The area under the plasma concentration-time 
curve (AUC) was determined according to the linear trapezoidal rule. For each pig and 
treatment, total bioavailability (AUCtotal) was calculated by adding up the AUC values of 
quercetin and its metabolites with an intact flavonol structure (isorhamnetin and tamarixetin). 
AUC data, maximum plasma concentration (cmax), and time at maximum plasma 
concentration (tmax) were analysed using repeated measures one-way ANOVA. The amount of 
dry matter from the gastric content and plasma flavonol concentrations of the rats were 
analysed using one-way ANOVA. Tukeys’ multiple comparison was applied as post-test 
(Graphpad Prism 4, Graphpad Software Inc., San Diego, CA, USA). A P-value <0·05 was 
considered significant. 
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RESULTS 
Bioavailability in pigs 
After administration of quercetin with the test meals to pigs, metabolites with an intact 
flavonol structure appeared in plasma within 30 min. Plasma levels of flavonols decreased 
below detection limit (7 nmol/L) within 24 h. In accordance with previous studies (Cermak et 
al. 2003; Lesser et al. 2004), the main metabolite after β-glucuronidase/sulfatase treatment of 
the pig plasma samples was quercetin, while isorhamnetin (3’-O-methyl quercetin) and 
tamarixetin (4’-O-methyl quercetin) were found in a proportion of approximately 10% each, 
irrespective of the dietary treatment.  
After intake of quercetin with the standard diet, the mean peak plasma concentration (cmax) 
was reached 95 min (tmax) after intake (Table III.2). Thereafter, quercetin levels with the 
standard diet decreased continuously until they were below detection limit after 24 h 
(Figure III.1).  
 
Table III.2: Pharmacokinetic parameters and relative bioavailability of quercetin in pigs after 
intake of quercetin in test meals differing in their fat content and/or fatty acid pattern* 
 
Diet§ cmax tmax AUCtotal 
Relative 
bioavailability 
 µmol/L min min x µmol/L % 
 Mean SEM Mean SEM Mean SEM  
Standard 0·323 0·038 95·0a 18·0 86·6b 11·3 100 
LCT 0·334 0·034 65·0a 5·0 96·7b 8·5 112 
MCT 0·288 0·030 170·0b 20·0 119·7a 8·7 138 
 
LCT, long-chain fatty acid triacylglycerols; MCT, medium-chain fatty acid triacylglycerols; cmax, 
maximum plasma concentration of quercetin; tmax, time between administration of test meal and the 
appearance of maximum plasma concentration of quercetin; AUCtotal, area under the plasma 
concentration-time curve from 0 to 24 h for the sum of quercetin and its metabolites isorhamnetin and 
tamarixetin. 
*Values are means of six pigs for each dietary treatment. 
a,bMean values within a column with unlike superscript letters were significantly different (P<0·05). 
§For composition of diets, see Table III.1. 
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Figure III.1: Plasma concentration-time curves of the main metabolite quercetin after oral 
administration of quercetin (30 µmol/kg BW) to pigs in test meals that differed in their fat 
content and/or fatty acid pattern 
Values are means for six pigs, with standard errors of the mean represented by vertical bars. For 
composition of diets, see Table III.1. (-●-), standard diet; (-○-), LCT diet; (-∆-), MCT diet; LCT, long-
chain fatty acid triacylglycerols; MCT, medium-chain fatty acid triacylglycerols. 
 
 
When the flavonol was administered together with LCT diet, the plasma concentrations of 
quercetin peaked already after 65 min. This was, however, not significantly different from 
intake with standard diet (Table III.2). At 8 h after meal intake, the plasma quercetin 
concentrations were 0·053 (SEM 0·008) and 0·029 (SEM 0·007) µmol/L for LCT and 
standard diet, respectively. 
After administration of quercetin together with the MCT diet, flavonol plasma concentrations 
rose steadily over 170 min until peak level (Table III.2), and thereafter declined continuously. 
At 8 h after intake, the mean plasma concentration was still higher (0·061 (SEM 0·009) 
µmol/L) than after intake with standard diet (P<0·05). At 12 h after meal intake, mean plasma 
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concentrations in all groups were equally low (Figure III.1). Maximum plasma concentrations 
of quercetin after intake with the three different diets were not significantly different. Total 
oral bioavailability (AUCtotal) of quercetin, however, was significantly higher after intake of 
quercetin with MCT diet than after intake with standard and LCT diet (Table III.2).  
 
Gastric emptying in rats 
Within 15 min, the rats consumed 5 g of the experimental diets which contained the same 
dietary concentration of quercetin as in the original pig test meals. This resulted in an intake 
of about 100 µmol quercetin/kg BW. One hour after consumption of the meals, blood samples 
and gastric contents were collected. Dry matter of gastric contents did not differ in weight 
(Figure III.2). About 80% of dry matter consumed remained in the stomach one hour after 
meal intake. 
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Figure III.2: Gastric content of rats 1 h after administration of 5 g test meals that differed in 
their fat content and/or fatty acid pattern (dry matter expressed as percentage of intake) 
All test meals contained approx. 100 µmol quercetin/kg BW. Values are means for six rats, with 
standard errors of the mean represented by vertical bars. For composition of diets, see Table III.1. 
(■), standard diet; (□), LCT diet; (≡), MCT diet; LCT, long-chain fatty acid triacylglycerols; MCT, 
medium-chain fatty acid triacylglycerols. 
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The flavonol plasma concentrations (sum of quercetin and methylated metabolites) 1 h after 
intake of quercetin were 3·736 (SEM 0·226), 3·619 (SEM 0·190), and 3·010 (SEM 0·243) 
µmol/L with the standard, LCT and MCT diet, respectively (P=0·073). The pattern of 
deconjugated quercetin metabolites in rats plasma differed from that found in pigs. In rats, the 
relative proportions of quercetin, isorhamnetin and tamarixetin in plasma were 52·3 (SEM 
1·3), 45·0 (SEM 1·4), and 4·9 (SEM 0·1) %, respectively (n = 18). As observed in pigs, 
dietary treatment did not influence proportions of methylated metabolites. 
 
 
DISCUSSION 
Effects of dietary co-ingestion of either LCT or MCT compared to a low-fat diet on the 
relative systemic availability of quercetin aglycone were investigated in the current pig study. 
In principle, the results obtained in the present study agree with the results of our previous 
study (Lesser et al. 2004). Again, the co-administration of dietary fat enhanced the 
bioavailability of quercetin in pigs. Compared to the previous study, however, the stimulatory 
effect of the LCT diet was less pronounced and failed to meet the level of significance. The 
AUC obtained for quercetin applied with MCT fat was significantly higher than with LCT or 
standard diet. Interestingly, quercetin absorption from the MCT containing test meal was 
substantially delayed, indicated by the relatively slow rise in plasma levels (Figure III.1) and 
the late tmax (Table III.2).  
One possible cause for this delay in quercetin absorption from MCT diet could have been a 
delayed gastric emptying of the MCT diet. In the literature, the mode of action of MCT fat on 
gastric emptying is discussed controversially. Some studies found that gastric emptying after 
intake of MCT or medium-chain fatty acids was more rapid than after intake of LCT or long-
chain fatty acids in humans (Hunt & Knox 1968) and rats (Harkins et al. 1964). Another study 
observed no difference in gastric emptying between LCT and MCT in rats (Maggio & 
Koopmans 1987), while other groups reported a retardation of gastric emptying by MCT in 
comparison to LCT. In rats, the gastric emptying of tridecanoylglycerol was found to be 
significantly slower than that of cocoa butter or rapeseed oil (Porsgaard et al. 2003). Pirk & 
Skala (1970) observed retarded gastric emptying in both rats and man by x-ray observation 
after administration of a MCT mixture compared to a lard mixture. Additionally, they found a 
delay in complete evacuation time of the small intestine after administration of MCT. 
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Thus, we investigated gastric emptying in rats after consumption of the specific experimental 
diets. Rats are a frequently used animal model for investigations on gastric emptying (see 
above) and were chosen in this experiment because of the easier handling of the greater 
number of animals required (here n = 18) compared to the pigs. Regulation of gastric 
emptying in rats and pigs in response to dietary fat seems to function similarly. Plasma levels 
of cholecystokinin (CCK), one major mediator in the complex interplay of nutritional, 
hormonal and neural factors regulating gastric emptying, were shown to elevate, among other 
triggers, in response to ingestion or intraduodenal administration of LCT or long-chain fatty 
acids in rats and pigs (Lilja et al. 1984; Cuber et al. 1990; Lewis & Williams 1990; Hölzer et 
al. 1994). Intravenous injection of active CCK-8 peptide dose-dependently evokes pylorus 
contraction and reduces intragastric pressure in rats, thus slowing gastric emptying down 
(Adelson et al. 2004). In pigs, gastric emptying was slowed in response to i.v. application of 
CCK-8 (Gregory et al. 1995), too, and i.v. application of a specific CCK peripheral receptor 
inhibitor reduced inhibition of gastric emptying triggered by duodenal fat infusion (Rayner & 
Miller 1993). In our experiment, no diet-related differences in gastric emptying were observed 
1 h after intake of the test meals. Thus, the delayed quercetin absorption from the MCT diet 
can probably not be explained by a slower gastric emptying. Some authors (Hopman et al. 
1984; Vu et al. 1999) observed that, in contrast to LCT, dietary MCT do not induce CCK 
release in man. Because CCK inhibits gastric motility, a lack in CCK secretion would result 
in an enhanced gastric emptying and thus cannot explain the results obtained in the present 
study. 
We also analysed the plasma flavonol levels at 1 h after meal intake. Interestingly, flavonol 
levels in rat plasma tended to be lower with the MCT diet. This was in accordance with the 
respective 1 h values in pigs, where we observed a significant difference (Figure III.1; 
P<0·05). This might indicate that absorption of quercetin was probably also delayed from the 
MCT diet in rats, despite the fact that quercetin absorption may already occur from rat 
stomach (Crespy et al. 2002). 
Although the MCT and LCT fat differ somewhat regarding their melting temperature (lard 26-
39 °C, C8:0 16·3 °C, and C10:0 31·3 °C), it can be assumed that both fats are fluid at body 
temperature. Conjugated bile acids are essential for the formation of mixed micelles which 
enhance the absorption of fat soluble substances including molecules deriving from luminal 
triacylglycerol hydrolysis. The rather lipophilic quercetin molecule might dissolve in the lipid 
phase of the chyme and mucosal uptake seems to be promoted in the presence of micelles 
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(Azuma et al. 2002) as presumably indicated by the accelerated absorption of quercetin from 
a lard containing diet, compared with a low-fat diet, found in our previous study (Lesser et al. 
2004). As already mentioned above, some authors (Hopman et al. 1984; Vu et al. 1999) 
observed that, in contrast to LCT, dietary MCT do not induce CCK release with subsequent 
gallbladder contractions in man. Thus, it can be assumed that in the pigs after ingestion of the 
MCT containing diet an emulsion without formation of mixed micelles will be present in the 
small intestinal contents. This might be one possible reason for a delayed absorption of 
quercetin from the MCT diet compared with the LCT-containing meal. 
An explanation for delayed absorption of quercetin from MCT diet compared to LCT or 
standard diet could be a shift of quercetin absorption from the duodenum to more distal parts 
of the small intestine, due to physico-chemical factors. Some authors reported an acceleration 
of duodenocecal transit time during administration of MCT fat (Ledeboer et al. 1995; Verkijk 
et al. 1997). As suggested by Vu et al. (1999) MCT, other than LCT, might not be rapidly 
absorbed in the proximal gut, but probably reach the ileocolonic region. An accelerated transit 
of quercetin containing chyme through the duodenum and proximal jeunum after ingestion 
with MCT diet, combined with a lower absorption from the proximal small intestine (due to 
solution in the lipophilic phase), could have shifted absorption of the flavonol to more distal 
segments of the small intestine. Assuming a more lipophilic nature of the chyme in the distal 
small intestine after MCT intake, a prolonged and intensified absorption of quercetin which 
resulted in higher accumulation in plasma could be feasible. In this context it is of interest that 
another lipid soluble substance, namely vitamin E, showed an enhanced bioavailability when 
administered with MCT in comparison to LCT (Gallo-Torres et al. 1978). 
Although the rats ingested a quercetin dosage only about three times higher than that applied 
to pigs, plasma levels after 1 h were at least ten times higher in rats. In addition, the pattern of 
methylated metabolites was also different between the two species. The higher proportion of 
isorhamnetin found in rat plasma in comparison to pig plasma might be due to a higher 
methylation activity exerted by catechol-O-methyltransferase (EC 2.1.1.6). These 
observations are in good agreement with findings from other groups (Manach et al. 1996; de 
Boer et al. 2005). Thus, the methylation pattern of quercetin metabolites in pigs seems to be 
more similar to humans (Hubbard et al. 2003) than to rats.  
The unexpected effect of delayed quercetin absorption with the MCT diet hampered the 
interpretation of the data with regard to the impact of either micelles or chylomicrons on 
quercetin bioavailability, as was the original intention of our study. However, we observed an 
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enhanced bioavailability of the flavonol quercetin when administered with a MCT containing 
diet. The absorption of quercetin was significantly delayed with that diet compared to a LCT 
containing diet or the low-fat standard pig ration. However, this was probably not due to 
slower gastric emptying of the MCT diet but may be caused by differences in the physico-
chemical nature of the chyme. The observed effect of MCT might be attributable to a shift of 
the absorption of fat soluble substances, including quercetin, to more distal parts of the small 
intestine.  
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Flavonoids, including the abundant flavonol quercetin, are bioactive plant components present 
in our daily diet. A wide spectrum of health promoting activities has been claimed for 
flavonols. These claims, however, are mainly deduced from in vitro studies. A prerequisite for 
potential in vivo effects of quercetin is of course a sufficient bioavailability of this polyphenol. 
Bioavailability in this context summarizes gastrointestinal absorption, distribution, and 
metabolism within the organism as well as excretion. The present work focuses on the 
flavonol quercetin, one of the most important flavonoids in terms of quantity of intake with 
Western-style human diets as well as with respect to potential biological activities. The aim of 
this thesis is to contribute to the knowledge on effects of dietary factors that influence 
bioavailability of quercetin. 
In the first study of this thesis (chapter II), the influence of the amount of dietary fat on the 
bioavailability of the flavonol quercetin was investigated in pigs. Thereby, the systemic 
availability of quercetin, applied as pure substance either as the aglycone or as the 3-O-
monoglucoside (Q3G) was monitored after intake with isoenergetic test meals that differed in 
fat content (3, 17, and 32%, wt/wt). In the second study (chapter III), possible influences of 
the fatty acid chain length of dietary triglacylglycerols (long- or medium-chain 
triacylglycerols) on quercetin bioavilability were examined. In this study, quercetin aglycone 
was again added as pure substance to test meals. The aglycone was applied in this study, 
because it has become increasingly clear during the last years, that flavonols have to be 
deglycosilated before absorption into the systemic circulation (see chapter I.3.2.). In addition, 
the enhancing effect of dietary fat on the bioavailability of quercetin observed in the first 
study was more pronounced when quercetin was applied as the aglycone compared to Q3G.  
The pig was chosen as model animal because of the high similarity between humans and pigs 
concerning the anatomy and physiology of the digestive and circulatory system (Almond, 
1996). In addition, larger volumes of blood can be obtained from a pig compared to a rat or 
mouse, allowing investigation of pharmacokinetics in each single animal. In general, there are 
various species differences with respect to morphology and physiology of the gastrointestinal 
tract (GIT). One example are differences in gastric mucosa types and distributions (Kararli, 
1995). Whereas in rats and pigs the cardia is lined by a non-secreting epthelium, such a pars 
proventricularis is absent in humans. Another example is, that pigs like humans have a gall 
bladder which functions as a contractible reservoir for bile. In contrast, rats lack a gall 
bladder, and, therefore, secrete bile more or less continuously (DeSesso & Jacobson, 2001) 
and independent from food intake (Edwards et al., 2001). The rat common bile duct is divided 
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into two morphologically and physiologically distinct parts. The hepatic part was found to be 
richly vascularized and contractile, and thus might partially replace a gall bladder (Carrier & 
Connat, 1995), whereas the duodenal part is less vascularized and not contractile, presumably 
acting as pancreatic duct (Carrier & Connat, 1995). From an anatomical study using scanning 
electron microscopy of rat intestine, bile storage in periportal plexi of bile ductules was 
suggested (Murakami et al., 2001). Nevertheless, the concentration of conjugated bile acids in 
rat bile was found to be lower compared to man (Andrews & Andrews, 1979). Therefore, 
although parts of the biliary duct system in rats may substitute for the missing gall bladder, a 
better comparability of fat digestion between pigs and humans can be assumed. 
In the second study an additional experiment using rats was performed, aimed to investigate a 
possible influence of medium-chain triacylglycerols (MCT) on gastric emptying (chapter III). 
To our best knowledge, there are no known species differences that would hamper an 
extrapolation of the results obtained in rats on gastric emptying in pigs or man, although the 
regulation of gastric emptying is very complex and yet unknown species differences might 
exist. In the rat study, no diet-related difference with respect to the remaining gastric contents 
were detected one hour after meal intake. This time point was chosen, because in pigs a 
significantly lower plasma quercetin concentration was observed with the MCT-containing 
test meal as compared to the long-chain triacylglycerols (LCT) diet (Figure III.1). The plasma 
quercetin concentration after one hour in the rats fed the same test meals as in the respective 
pig study tended to be lower. This must be, however, interpreted with some caution, because 
no complete pharmacokinetic study was conducted in the rats. Although the results did not 
indicate a delayed gastric emptying after intake of the MCT-containing meal, a delay in 
gastric emptying cannot be completely ruled out as one possible reason for the later 
appearance of quercetin in the systemic circulation. Because gastric emptying in pigs has been 
observed to be somewhat faster than in other species (Gregory et al., 1995), and because only 
~20% of gastric content have been emptied from the rat stomachs one hour after meal intake 
(Figure III.2), a later time point might have been more appropriate.  
The amount of diet administered was adjusted to a meal size of 5 g per serving for the rats. No 
differences in gastric emptying were observed after intake of the different diets. Compared 
with the situation in the pig trial, it must be kept in mind, that the relative meal size in the rat 
study (5 g, ~250 g BW) was much larger than in the pig study (162 or 200 g, ~35 kg BW). 
Thus, gastric distention which also modifies gastric emptying was different in rats and pigs.  
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With regard to the known mechanisms of gastric emptying, which include, among others, the 
gastrointestinal peptide hormone cholecystokinin (CCK) as one major player, it was 
somewhat surprising that consumption of the LCT diet did not result in a slower gastric 
emptying than the other two diets, because LCT or long-chain fatty acids are known to 
stimulate CCK release from the duodenal mucosa (Lewis & Williams, 1990). CCK in turn, is 
known to retard gastric emptying (Adelson et al., 2004; Rayner & Miller, 1993). Again, one 
hour after meal intake might have been to early to detect any differences. 
In both studies of this thesis, quercetin was supplemented to pigs (~35 kg BW) at a level of 30 
µmol kg-1 BW, which equals 10 mg kg-1 BW. This resulted in a single dose of ~350 mg 
quercetin (either as the aglycone or Q3G) consumed with the test meals. Thus, the amount of 
quercetin ingested by the pigs in these trials exceeded estimated mean daily dietary quercetin 
intake in humans ~20fold (Hertog et al., 1993). The main reason for choosing this dosage was 
to ensure that measurable plasma concentrations were achieved in pigs by the single test meal. 
Although the dose applied in these studies was clearly above the average dietary intake of 
quercetin in humans, one has to keep in mind that intake of flavonoid enriched food 
supplements (functional food) and a more selective intake of food components with high 
quercetin content, e.g. onions, might result in a considerably higher quercetin intake in 
humans. 
To investigate effects of food on flavonoid pharmacokinetics, Manach & Donovan (2004) 
recently proposed to firstly administer the flavonoid containing food by itself, and then to test 
the hypothesis that certain macronutrients consumed together with that food significantly alter 
flavonoid pharmacokinetics, in order to facilitate comparisons between studies, different 
flavonoids and food sources. In the current studies, quercetin was always applied as pure 
substance (aglycone or Q3G) mixed among test meals varying in composition. Thereby, 
effects of co-ingested nutrients were investigated to evaluate their influence on the 
bioavailability of quercetin. Thus, this approach does not take into account possible effects of 
the food matrix and therefore might not truly reflect bioavailability of quercetin from natural 
food sources. Nevertheless, this approach enables the investigation of principle influences of 
food components on the bioavailability of quercetin. 
In chapter I.3.2., species differences in the activity of flavonol metabolising enzymes, which 
may result in different metabolite patterns, as well as species differences in the binding 
affinity of serum albumin against flavonoids, influencing their terminal elimination half-life, 
as well as potential variations in urinary excretion have been shortly addressed. In addition to 
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such species differences, striking inter-individual differences within a species in quercetin 
bioavailability were reported in the majority of the respective studies (Németh et al., 2003; 
Graefe et al., 2001; da Silva et al., 1998; Hollman et al., 1995). These inter-individual 
variations might be attributable to a variety of causes, like individual enzyme expression and 
activities (Németh et al., 2003), bacterial colonisation of the intestine, and/or variations in 
levels of transporters, enabling more efficient absorption or secretion of flavonols (Manach et 
al., 2005). Manach et al. (2005) recently compiled data on the bioavailability of quercetin 
from 14 human studies after oral intake of quercetin from different sources and calculated 
mean pharmacokinetic parameters. Thereby, the authors assumed a linear dose-response 
relationship of cmax, which, however, can only be assumed to occur at low dietary 
concentrations of quercetin and which is not confirmed by the majority of respective studies. 
An overview on quercetin bioavailability parameters obtained in human bioavailability 
studies with a comparable amount of quercetin intake originating from different sources is 
presented in Table IV.1. 
 
Table IV.1: Pharmacokinetic parameters and urinary fractional excretion of intact quercetin in 
humans after consumption of ~100 mg quercetin equivalents as aglycone, glycosides, or 
with fooda 
 
Quercetin source cmax (plasma) 
tmax 
(plasma) 
Elimination 
half-life t1/2 
Excretion 
(urine) n 
Quantity of ingestion: 
~100 mgb µmol L
-1  min  h % of dose  
Apple meal 0.3  150  23  0.4 91 
Onion supplement 7.6  41  10.9  6.4d 123 
Onion supplement  
(68 mg quercetin) 0.7  42  28  1.4 9
1 
Q3G, pure compound 5.0  37  18.5  3.6d 94 
Q4’G, pure compound 3.5  <30  21.6  n.d.c 92 
Q4’G, pure compound 6.9  42  11.9  4.5d 123 
Q4’G, pure compound 4.5  27  17.7  3.1d 94 
Rutin, pure compound 0.3  558    -  0.4 91 
Rutin, pure compound 0.2  360  28.1  n.d. 92 
(modified from Day & Williamson, 2003, and Scalbert & Williamson, 2000) 
aFlavonol conjugates in plasma and urine were hydrolysed by acid or enzymes before 
chromatographic or colorimetric analysis, bquercetin aglycone equivalent, cn.d. = not determined, 
dsum of excreted flavonols, 1(Hollman et al., 1997), 2(Hollman et al., 1999), 3(Graefe et al., 2001), 
4(Olthof et al., 2000). 
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Although the pigs used in each trial of the current studies were taken from the same litter, 
inter-individual variations were also observed. Therefore, each animal was subjected to each 
treatment, thus serving as its own ‘control’, to avoid masking of effects of food components, 
e.g. dietary fat, by inter-individual variations in the overall handling of quercetin. 
In the first trial presented in this thesis (chapter II), a significant enhancing effect of LCT 
(~54%) on the bioavailability of quercetin could be documented. Some of the factors 
mentioned above might also have been responsible for the failure in reaching the level of 
significance with respect to the influence of LCT on the bioavailability of quercetin in the 
second trial (non-significant increase of 12%, chapter III). Such problems might be eliminated 
by using a larger number of animals per trial. 
In the first study, 10 mg quercetin kg-1 BW was administered to the pigs in the form of Q3G, 
yielding maximum plasma concentrations within the range of 0.9-0.6 µmol L-1. Compared to 
the studies cited in Table IV.1, where approximately 1.4 mg quercetin equivalent kg-1 BW 
have been administered, the maximum plasma levels reached in humans seem to be 
considerably higher than in pigs. Similarly, in the second study, comparison of the post-
absorptive plasma levels at 1 h after intake in pigs and rats revealed that plasma levels (at 
least at this time point) in rats are considerably higher than in pigs (chapter III). One possible 
explanation for the substantially lower quercetin concentrations in pigs as compared to 
humans and rats (normalized to an equivalent dietary dose of quercetin) might be a more 
efficient first pass elimination (intestinal mucosa, liver) in pigs. 
In general, cmax of plasma quercetin after application of quercetin monoglucosides is reached 
within ~1.1 h (0.5-2.9 h, tmax) after oral intake in humans, rats and pigs (Manach et al., 2005; 
Cermak et al., 2003; Aziz et al., 1998; Hollman et al., 1996). Thus, the results obtained with 
low fat and LCT diets in the present experiments are well within this range (chapters II and 
III). In both current studies, a higher plasma level at later time points (~8 h after intake) were 
consistently observed after intake of quercetin with the LCT-containing meal as compared to 
the low fat test meal (although not significant in the second study). This phenomenon might 
be due to some enterohepatic recycling of quercetin (chapter I.3.3.4.), which might be 
intensified in the presence of LCT within the chyme. Hints for an enterohepatic recycling of 
quercetin in pigs have also been observed in earlier studies (Ader et al., 2000).  
As pointed out earlier, one aim of the second study of this thesis was to get some insight into 
the possible involvement of lymphatic absorption of quercetin after co-administration with 
dietary lipids and to further elucidate the mechanisms responsible for the higher 
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bioavailability of quercetin from lard-enriched test meals as compared to low-fat control. Two 
reasons were theoretically considered to explain this finding: (1) A better solubility of the 
relatively lipophilic quercetin aglycone in the intestinal tract in the presence of fat and/or (2) 
the integration of quercetin into chylomicrons with subsequent lymphatic absorption. In the 
first case, an increased absorption from fat containing diets should be largely independent of 
the type of dietary fat. On the other hand, formation of chylomicrons is largely restricted to 
the absorption of LCT or long-chain fatty acids, because MCT or medium-chain fatty acids 
are absorbed directly into the portal vein (Harkins & Sarett, 1968; Bloom et al., 1951). 
Lymphatic absorption of quercetin could enhance quercetin bioavailability due to bypassing 
of the liver, which might reduce biliary elimination during the first liver passage (first pass 
effect). If this was true, only fats containing LCT should increase the bioavailability of 
flavonols but not fats comprised of MCT due to the different handling of LCT and MCT 
during intestinal absorption. As already discussed (chapter III), the interpretation of the results 
was somewhat hampered by the unexpected finding, that the MCT-containing meal 
significantly delayed the absorption of quercetin. Nevertheless, both types of dietary fat 
enhanced the bioavailability of quercetin. Thus, both mechanisms pointed out above may be 
of relevance with respect to the influence of dietary lipids on the bioavailability of quercetin. 
It appears, that the formation of chylomicrons accelerates absorption of quercetin from chyme 
(only relevant for LCT) and that the more lipophilic nature of chyme after ingestion of both 
types of dietary lipids (LCT and MCT) may promote a more extensive absorption of dietary 
quercetin. Further investigations on flavonoid content of lymph are needed to get conclusive 
information on this potential uptake pathway. In a very recent study, quercetin was detected in 
lymph of rats (Murota & Terao, 2005). In this study, quercetin was administered within a 
propylene glycol/water mixture, and no fat was administered. Quercetin appeared in the 
lymph within 30 min, similar to its appearance in blood. In a proceeding study of the same 
group conducted under similar conditions, administration of the same amount of quercetin to 
rats resulted in clearly higher plasma flavonol levels (da Silva et al., 1998) compared to the 
lymphatic concentrations of quercetin reported in the later study (cmax = 3.1 µM, 
tmax = 30 min) (Murota & Terao, 2005). 
 
Methylation of quercetin 
Methylation of quercetin occurs in different species as part of the detoxification reactions in 
gut and liver (Donovan et al., 2001; Moon et al., 2000; Manach et al., 1999; Piskula & Terao, 
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1998; Manach et al., 1997; Hollman et al., 1997). Main molecular sites for O-methylation of 
quercetin are the 3’- and 4’-hydroxyl groups, yielding isorhamnetin or tamarixetin, 
respectively. Differences in the pattern of methylated metabolites of quercetin have been 
observed between species. Morand et al. (2000) reported that the methylated quercetin 
derivatives isorhamnetin and tamarixetin accounted for ~50% of flavonols (with only minor 
amounts of tamarixetin) 3.5 h post dosing of 20 mg of quercetin equivalents in rats. At time 
points ≥7 h, the concentration of these monomethylated quercetin derivatives reached 70-
77%. Similar plasma concentrations of isorhamnetin were also observed in another rat study 
(Manach et al., 1997). In the own rats experiment (chapter III), ~50% of total flavonols were 
present as quercetin, ~45% isorhamentin and only ~5% tamarixetin were observed at 1 h post-
dosing (100 µmol kg-1 BW) which is in good agreement with other rat studies. In humans, 
~20-40% of absorbed quercetin is methylated in the 3’-position, yielding isorhamnetin 
(Graefe et al., 2001; Olthof et al., 2000; Erlund et al., 2000). In human blood samples, after a 
5 d period with intake of flavonoids-rich fruits and vegetables, using the same method applied 
for analysis of pig plasma samples in the current studies, ~80% of quercetin and only ~20% of 
both isorhamnetin and tamarixetin were detected (Hubbard et al., 2003). In pigs, consistently 
a fraction of ~6-11% of isorhametin and of 5-18% of tamarixetin with the remainder being 
present as non-methylated quercetin were found (chapter II and III) (Cermak et al., 2003; 
Ader et al., 2000). Thus, methylation seems to be species-dependent but may also vary 
depending on the dose of quercetin applied. 
 
 
REFERENCES 
Adelson DW, Million M, Kanamoto K, Palanca T & Taché Y (2004) Coordinated gastric and 
sphincter motility evoked by intravenous CCK-8 as monitored by ultrasonomicrometry in rats. 
Am J Physiol Gastrointest Liver Physiol 286, G321-G332. 
Ader P, Wessmann A & Wolffram S (2000) Bioavailability and metabolism of the flavonol quercetin 
in the pig. Free Radic Biol Med 28, 1056-1067. 
Almond GW (1996) Research applications using pigs. Vet Clin North Am Food Anim Pract 12, 707-
716. 
Andrews CJ & Andrews WH (1979) The relation between structure and function of bile ducts in man, 
some laboratory animals and the Adelie penguin. Q J Exp Physiol Cogn Med Sci 64, 61-67. 
 
 GENERAL DISCUSSION 79 
Aziz AA, Edwards CA, Lean ME & Crozier A (1998) Absorption and excretion of conjugated 
flavonols, including quercetin-4'-O-beta-glucoside and isorhamnetin-4'-O-beta-glucoside by 
human volunteers after the consumption of onions. Free Radic Res 29, 257-69. 
Bloom B, Chaikoff IL & Reinhardt WO (1951) Intestinal lymph as pathway for transport of absorbed 
fatty acids of different chain lengths. Am J Physiol 166, 451-455. 
Carrier N & Connat JL (1995) Rat common bile duct: structure, pharmacological responsiveness, 
CGRP innervation, and binding sites. Gen Comp Endocrinol 100, 197-210. 
Cermak R, Landgraf S & Wolffram S (2003) The bioavailability of quercetin in pigs depends on the 
glycoside moiety and on dietary factors. J Nutr 133, 2802-2807. 
da Silva EL, Piskula MK, Yamamoto N, Moon JH & Terao J (1998) Quercetin metabolites inhibit 
copper ion-induced lipid peroxidation in rat plasma. FEBS Lett 430, 405-408. 
Day AJ & Williamson G (2003) Absorption of quercetin glycosides. In Flavonoids in health and 
disease, pp. 391-412 [C Rice-Evans and L Packer, editors]. New York: Marcel Dekker, Inc. 
DeSesso JM & Jacobson CF (2001) Anatomical and physiological parameters affecting 
gastrointestinal absorption in humans and rats. Food Chem Toxicol 39, 209-228. 
Donovan JL, Crespy V, Manach C, Morand C, Besson C, Scalbert A & Remesy C (2001) Catechin is 
metabolized by both the small intestine and liver of rats. J Nutr 131, 1753-1757. 
Edwards GA, Porter CJ, Caliph SM, Khoo SM & Charman WN (2001) Animal models for the study 
of intestinal lymphatic drug transport. Adv Drug Deliv Rev 50, 45-60. 
Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J, Parantainen J & Aro A (2000) 
Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J 
Clin Pharmacol 56, 545-53. 
Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, 
Derendorf H & Veit M (2001) Pharmacokinetics and bioavailability of quercetin glycosides in 
humans. J Clin Pharmacol 41, 492-499. 
Gregory PC, McFadyen M & Rayner DV (1995) Control of gastric emptying in the pig: influence of 
cholecystokinin, somatostatin and prokinetic agents. Exp Physiol 80, 159-165. 
Harkins RW & Sarett HP (1968) Medium-chain triglycerides. JAMA 203, 272-274. 
Hertog MGL, Hollman PCH, Katan MB & Kromhout D (1993) Intake of potentially anticarcinogenic 
flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 20, 21-9. 
Hollman PCH, Bijsman MNCP, van Gameren Y, Cnossen EPJ, de Vries JHM & Katan MB (1999) 
The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in 
man. Free Radic Res 31, 569-573. 
Hollman PCH, de Vries JHM, van Leeuwen SD, Mengelers MJB & Katan MB (1995) Absorption of 
dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62, 
1276-1282. 
Hollman PCH, van Trijp JMP, Buysman MNCP, van der Gaag MS, Mengelers MJB, de Vries JHM & 
Katan MB (1997) Relative bioavailability of the antioxidant flavonoid quercetin from various 
foods in man. FEBS Lett 418, 152-156. 
 
 CHAPTER IV 80
Hollman PCH, vd Gaag M, Mengelers MJB, van Trijp JM, de Vries JHM & Katan MB (1996) 
Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic 
Biol Med 21, 703-7. 
Hubbard GP, Wolffram S, Lovegrove JA & Gibbins JM (2003) The role of polyphenolic compounds 
in the diet as inhibitors of platelet function. Proc Nutr Soc 62, 469-478. 
Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of 
humans and commonly used laboratory animals. Biopharm Drug Dispos 16, 351-380. 
Lewis LD & Williams JA (1990) Regulation of cholecystokinin secretion by food, hormones, and 
neural pathways in the rat. Am J Physiol 258, G512-G518. 
Manach C & Donovan JL (2004) Pharmacokinetics and metabolism of dietary flavonoids in humans. 
Free Radic Res 38, 771-785. 
Manach C, Morand C, Demigne C, Texier O, Regerat F & Remesy C (1997) Bioavailability of rutin 
and quercetin in rats. FEBS Lett 409, 12-6. 
Manach C, Texier O, Morand C, Crespy V, Regerat F, Demigne C & Remesy C (1999) Comparison of 
the bioavailability of quercetin and catechin in rats. Free Radic Biol Med 27, 1259-1266. 
Manach C, Williamson G, Morand C, Scalbert A & Remesy C (2005) Bioavailability and bioefficacy 
of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81, 230S-
242S. 
Moon JH, Nakata R, Oshima S, Inakuma T & Terao J (2000) Accumulation of quercetin conjugates in 
blood plasma after the short-term ingestion of onion by women. Am J Physiol Regul Integr 
Comp Physiol 279, 461-7. 
Morand C, Manach C, Crespy V & Remesy C (2000) Respective bioavailability of quercetin aglycone 
and its glycosides in a rat model. Biofactors 12, 169-174. 
Murakami T, Sato H, Nakatani S, Taguchi T & Ohtsuka A (2001) Biliary tract of the rat as observed 
by scanning electron microscopy of cast samples. Arch Histol Cytol 64, 439-447. 
Murota K & Terao J (2005) Quercetin appears in the lymph of unanesthetized rats as its phase II 
metabolites after administered into the stomach. FEBS Lett 579, 5343-5346. 
Németh K, Plumb GW, Berrin JG, Juge N, Jacob R, Naim HY, Williamson G, Swallow DM & Kroon 
PA (2003) Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical 
step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur J Nutr 
42, 29-42. 
Olthof MR, Hollman PCH, Vree TB & Katan MB (2000) Bioavailabilities of quercetin-3-glucoside 
and quercetin-4'-glucoside do not differ in humans. J Nutr 130, 1200-3. 
Piskula MK & Terao J (1998) Accumulation of (-)-epicatechin metabolites in rat plasma after oral 
administration and distribution of conjugation enzymes in rat tissues. J Nutr 128, 1172-1178. 
Rayner DV & Miller S (1993) Voluntary intake and gastric emptying in pigs: effects of fat and a CCK 
inhibitor. Physiol Behav 54, 917-922. 
Scalbert A & Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130, 
2073S-2085S. 
 
 
  
 APPENDIX I 82
PREPARATION OF PLASMA SAMPLES AND HPLC CONDITIONS 
Flavonol compounds were extracted from plasma samples according to a method used by 
Morand et al. (1998). Pig plasma (980 µL) was spiked with 20 µL rhamnetin (50 µg/mL), 
used as an internal standard, and acidified to pH 4.9-5.0 with 130 µL acetic acid (0.583 M). 
This is the optimal pH for the enzyme glucuronidase/sulfatase. Probes were vortexed 
thoroughly. For deconjugation of flavonols circulation in plasma, 75 µL of 
β-glucuronidase/sulfatase (crude enzyme extract type H-2 of Helix pomatia, ~130 000 U/mL 
glucuronidase and ~400 U/mL sulfatase, Sigma-Aldrich) were added and samples were 
incubated for 60 min while gently shaking in a water bath. The reaction was stopped by 
adding 5.5 mL acetone, the resulting mixture was shaken horizontally for 20 min, and 
centrifuged for 45 min (4 °C, 3700 g). Supernatants were evaporated under partial vacuum for 
~5 h at 45 °C (Speed-Vac AES 1010, Savant Instruments Inc.) until dryness. The residual 
pellet was resuspended in 200 µL methanol by vortexing and ultrasonication (15 min). Aqua 
bidest. (77.5 µL) and 22.5 µL HCl aq. (10 M) were added, and the mixture was vortexed and 
centrifuged again at room temperature for 10 min at 16000 g. 200 µL of the supernatant were 
used for analysis and placed in the cooled autosampler (4 °C) of the HPLC apparatus. 
 
CHROMATOGRAPHIC CONDITIONS 
HPLC analysis was performed according to the method of Hollman et al. (1996). In principal, 
chelate complexes of intact flavonols with aluminium ions were detected after postcolumn 
derivatisation using a fluorescence detector. This method is restricted to analysis of intact 
flavonols containing a free 3-hydroxyl and 4-keto group at the C-ring which forms a 
fluorescent complex with Al3+. 
The HPLC system used (Jasco Labor- und Datentechnik GmbH Deutschland) included an 
autosampler (AS-2057 Plus), a degasser (DG-1580-54) and an isocratic pump (PU-1580) for 
the solvent, a second isocratic pump for the postcolumn reactant (PU-980), a column oven, 
and a fluorescence detector (FP-920). For HPLC analysis, 30 µL of the sample were injected 
onto a reversed phase C-18 Kromasil 100 column (250 x 4 mm, 5 µm particle size, Jasco 
Labor- und Datentechnik GmbH Deutschland), protected by a C-18 Inertsil ODS-2 column 
(10 x 4 mm, 5 µm particle size, Jasco Labor- und Datentechnik GmbH Deutschland). As the 
mobile phase, a buffered solution of 0.025 M sodium-dihydrogene-phosphate (pH 2.4), 
acetonitrile, and methanol (68:27:5 v/v), pH 2.96 was used at a flow rate of 1 mL/min. The 
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column effluent was mixed with the reagent (1 M Al(NO3)3 in methanol containing 7.2% 
(v/v) acetic acid) at a flow rate of 0.4 mL/min in a postcolumn reactor (6 m, 0.5 mm inner 
diameter, teflon tubing, plaited) connected to the HPLC column via a low-dead-volume tee. 
The column and the reactor were placed in the column oven set at 30 °C. The fluorescence of 
the ensuing flavonol-metal complex was measured at 485 nm, with an excitation wavelength 
of 422 nm. Flavonols were identified by comparison of retention time to that of standard 
substances. 
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FATTY ACID COMPOSITION OF LARD 
In the experiments of this thesis, lard is used as a typical dietary source of long-chain 
triacylglycerols (LCT) for creating the test meals. In lard triacylglycerols of the types SUU, 
USU and UUU (with U = unsaturated fatty acid, and S = saturated fatty acid) are abundant. 
The typical fatty acid composition of lard is given in Table A. 
 
Table A: Mean fatty acid composition of lard (Belitz & Grosch, 1992) 
 
fatty acid % (wt/wt) 
12:0 0.0 
14:0 2.0 
14:1 (9) 0.5 
16:0 24.0 
16:1 (9) 4.0 
  
fatty acid % (wt/wt) 
18:0 14.0 
18:1 (9) 43.0 
18:2 (9, 12) 9.0 
18:3 (9, 12, 15) 1.0 
20:0 0.5 
20:1, and 20:2 2.0 
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